Review Article

Novel Insights into miRNA in Lung and Heart Inflammatory Diseases

Amit Kishore, Jana Borucka, Jana Petrkova, and Martin Petrek

1 Laboratory of Immunogenomics and Immunoproteomics, Department of Pathological Physiology, Faculty of Medicine and Dentistry, Palacky University, Hnevotinska 3, 77515 Olomouc, Czech Republic
2 Department of Internal Medicine I-Cardiology, Faculty of Medicine and Dentistry, Palacky University, 77520 Olomouc, Czech Republic

Correspondence should be addressed to Amit Kishore; amitkishore.bio@gmail.com

Received 15 November 2013; Revised 3 March 2014; Accepted 21 April 2014; Published 27 May 2014

MicroRNAs (miRNAs) are noncoding regulatory sequences that govern posttranscriptional inhibition of genes through binding mainly at regulatory regions. The regulatory mechanism of miRNAs are influenced by complex crosstalk among single nucleotide polymorphisms (SNPs) within miRNA seed region and epigenetic modifications. Circulating miRNAs exhibit potential characteristics as stable biomarker. Functionally, miRNAs are involved in basic regulatory mechanisms of cells including inflammation. Thus, miRNA dysregulation, resulting in aberrant expression of a gene, is suggested to play an important role in disease susceptibility. This review focuses on the role of miRNA as diagnostic marker in pathogenesis of lung inflammatory diseases and in cardiac remodelling events during inflammation. From recent reports, in this context, the information about the models in which miRNAs expression were investigated including types of biological samples, as well as on the methods for miRNA validation and prediction/definition of their gene targets are emphasized in the review. Besides disease pathogenesis, promising role of miRNAs in early disease diagnosis and prognostication is also discussed. However, some miRNAs are also indicated with protective role. Thus, identifications and usage of such potential miRNAs as well as disruption of disease susceptible miRNAs using antagonists, antagomirs, are imperative and may provide a novel therapeutic approach towards combating the disease progression.

1. Introduction

The small microRNAs (miRNAs), 19–24 nucleotides, are noncoding, endogenous, single stranded, and evolutionarily conserved sequences. miRNAs downregulate gene expression at transcriptional or posttranscriptional level by binding to messenger RNAs (mRNAs) and preventing them from being translated into proteins [1]. They have an important role in biological processes, such as cellular development, differentiation, proliferation, and apoptosis. With the discovery of first miRNA lin-4 in 1993 [2] and later let-7 in 2000 within Caenorhabditis elegans during its developmental stage transitions [3, 4], as research advances, the information on miRNAs has grown exponentially and suggested them as one of the central players of gene expression regulation. For nomenclature purpose, they are numbered as per the order of their discovery. As each miRNA is able to target hundreds of transcripts, it has been estimated that miRNAs may regulate up to 30% of the protein-coding genes accounting for 1–5% of all predicted human genes [5]. For humans, to date, over 1,872 precursors hairpin sequences and 2,578 mature miRNAs have been reported (Sanger miRBase version 20; assembly count-GRCh37.p5) which can regulate important physiological processes and pathogenesis of several diseases. This review aims to summarize the current understanding of miRNAs in lung diseases and cardiac remodeling events implicated in inflammation and their potential role as biomarkers.

1.1. MicroRNA Biogenesis, Mechanism of Action, and Regulation. miRNAs are transcribed by RNA polymerase II as long precursor (up to several hundred nucleotides) originating as RNA sequences with hairpin structure of about 70–100 nucleotides in length that constitutes the primary transcript of the miR/primary miRNAs (pri-miRNAs).
These are further processed in the nucleus by microprocessor complex consisting of RNase III enzyme Drosha and double-stranded RNA binding protein, Pasha (also called DiGeorge syndrome Critical Region 8; DGCR8) to precursor-miRNAs (pre-miRNAs) of approximately 65 nucleotides. These pre-miRNAs are then exported to cytoplasm by exportin-5. This exportin-5 mediated transport to the cytoplasm is energy-dependent, which utilizes GTP bound to the Ran protein as cofactor [6].

In cytoplasm, the hairpin loop is removed and subsequently processed by the RNase III enzyme Dicer along with two double-stranded RNA (dsRNA) binding proteins, protein activator of PKR (PACT) and transactivation response RNA-binding protein (TRBP), leaving mature miRNA duplex (miRNA-miRNA*) of about 22 nucleotides in length with mismatch base [7] (Figure 1). Further, one of the two strands of the mature miRNA is loaded into the RNA-induced silencing complex (RISC) containing enzymes of Argonaute (Ago) family and is commonly guided to the 3′-untranslated region (UTR) of target mRNA. miRNAs anneal with sequences via Watson-Crick base pairing, although there are some examples of miRNA interactions within mRNA coding regions, intron-exon junctions and 5′-UTR. With the activity of Ago-2 where it blocks translation and promotes deadenylation (degradation of poly-A tail) resulting in mRNA degradation, the two mechanisms result in gene silencing [8]. The expression level and involvement of the ribonucleases Drosha, Dicer, and Argonaute-2 (Ago2) in processing and activity of miRNAs demonstrate a relationship with the phenomenon of RNA interference.

Regarding miRNA regulation, in addition to the major stages of control during miRNA biogenesis and its subcellular localization suggested by O’Connell et al. [9] and Yue [10], single nucleotide polymorphisms (SNPs) in the binding domain (seed region) could alter miRNA function. For example, a SNP in the 3′-UTR of asthma susceptibility gene HLA-G influences the targeting of miR-148a, miR-148b, and miR-152 [11].

1.2. miRNA Polymorphism in Regulation of Target Gene Expression. Mutations in miRNA transcripts are common and SNPs in pre-miRNAs could alter miRNA processing, expression, and/or binding to target mRNA and thus may have functional importance. Numerous reports have been
made for the impact of single nucleotide polymorphism in miRNAs (mirSNPs) towards disease susceptibility; however, in this review, focus will be made on inflammatory lung and cardiovascular diseases.

In a case-control study for risk factor for asthma, SNPs demonstrated risk variant rs2910164* C allele (C/G) in the pre-miRNA of miR-146a and rs2292832* T (C/T) miR-149 were significantly associated with lower risk of asthma [12] (Table I). Corroborating the finding, Jimenez-Morales et al. reported rs7079 (C/A) in Angiotensinogen (AGT) 3’-UTR affecting miR-31 and miR-584 were reported to be associated with HT [38].

Among the roles of mirSNPs in pathogenesis of cardiovascular diseases (CVDs), the mirSNPs rs5186* C (A/C) in human angiotensin II type 1 receptor (AGTRI) 3’-UTR affecting miR-155 binding site [35, 36] and rs9818870 (C/T) in muscle RAS oncogene homolog (MRAS) 3’-UTR modulating miR-195 and miR-135 were proposed to be potentially involved in the hypertension (HT) and other related CVDs [37]. Recently, rs7079 (C/A) in Angiotensinogen (AGT) 3’-UTR affecting miR-31 and miR-584 were reported to be associated with HT [38].

For coronary heart disease, the GG genotype of miR-149 rs4846049 (G/T) in the 3’-UTR of 5,10-methylenetetrahydrofolate reductase (MTHFR) was significantly associated with the increased risk [39]. For dilated cardiomyopathy (DCM), rs11614913*T (C/T) miR-196a2 and rs3746444*G (A/G) miR-499 were found to be significantly associated with increased risks [41]. In a genotype-phenotype correlation analysis for congenital heart disease risk, CC genotype of rs11614913 (T/C) miR-196a2 was associated with a significantly increased susceptibility (p = 6.81 × 10^-6) and increased mature miR-196a expression (P = 0.001) [24]. Few databases for miRNA-related genetic variants are Patrocles, dbSMR, PolymiRTS, MicroSNiPer, miRdsNP, and dPORE-miRNA [42].

These studies suggest the potentiality of genetic variant in disease susceptibility. In future, the allelic variant with low disease susceptibility could be explored in therapeutic mechanism to manage the disease progression.

1.3. miRNA in Epigenetics. miRNAs and antisense RNAs are able to direct epigenetic changes, such as histone modifications (e.g., H3K9me2, H3K9me3, and H3K27me3) and DNA methylation at specific loci, thereby evoking heritable and stable silencing of some mammalian imprinted genes. Histone modification involves Agol of RISC and the chromodomain protein Chp1 that recognizes H3K9me [43]. For DNA methylation, methyl groups are transferred to carbon-5 of cytosines by DNA methyltransferases (DNMT1 or DNMT3A and DNMT3B). Other enzymatic effectors of the epigenetic machinery include histone deacetylases (HDACs) and polycomb repressor complexes (PRCI or PRC2). In general, CpG sites flanking the promoter region are hypomethylated in transcriptionally active genes and hypermethylated in inactive genes.

The downregulation of epigenetically controlled miRNAs as well as epi-miRNAs that target elements of the epigenetic machinery [10, 44] has most notably been reported in cancer cells [45]. The first evidence of epi-miRNAs was reported in lung cancer, where miR-29 (a–c) family was shown to directly target the de novo enzymes DNMT3A and DNMT3B [46]. In this model system, few examples of epigenetic regulation of miRNAs with oncogenic properties include hypomethylation of miR-21 [44, 47] and let-7a-3 [48] and hypermethylation of miR-34b/c [49, 50]. However, hypermethylation of CpG island of miR-34a has been proposed with tumor suppressor role [44, 51].

For the pathogenesis of autoimmune disease, such as systemic lupus erythematosus (SLE), the first report on role of
# Table 1: Role of miRNA SNPs in lung inflammatory disease and cardiac remodeling events.

| MicroRNA                        | SNP* risk variant (alleles) | Location                                      | Putative role                                                                                                                                  | References |
|---------------------------------|----------------------------|-----------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|------------|
| **Asthma**                      |                            |                                               |                                                                                                                                             |            |
| miR-146a                        | rs2910164 C (C/G)          | Pre-miRNA region of miR-146a                  | Protection/lower risk of asthma                                                                                                              | [12, 13]   |
| miR-149                         | rs229832 T (C/T)           | Pre-miRNA region of miR-149                   | Associated with lower risk of asthma                                                                                                          | [12]       |
| miR-152 family (miR-148a, -148b, and -152) | rs1063320 G (C/G)          | HLA-G 3’-UTR (at + 342) position              | Protective against asthma only in children of asthmatic mothers                                                                            | [11, 15]   |
| **Chronic obstructive pulmonary disease (COPD)** |                            |                                               |                                                                                                                                             |            |
| miR-196a2                       | rs1641913 C (C/T)          | Pre-miRNA region of miR-196a2                 | Target Hoxb8; decreased risk factor                                                                                                          | [25]       |
| miR-499                         | rs3746444 G (A/G)          | Pre-miRNA regions of hsa-miR-499              | Decreased risk factor                                                                                                                         | [25]       |
| **Cystic fibrosis (CF)**        |                            |                                               |                                                                                                                                             |            |
| miR-433 and -509-3p              | rs10234329 (A/C)           | CFTR 3’-UTR                                   | Mild CFTR mutation and may have a role in pathogenesis of CF                                                                              | [33]       |
| **Pulmonary tuberculosis (PTB)**|                            |                                               |                                                                                                                                             |            |
| miR-499                         | rs3746444 C (T/C)          | Pre-miRNA regions of hsa-miR-499              | Disease susceptibility varies among different populations                                                                                | [25]       |
| miR-146a                        | rs2910164 G (G/C)          | Precursor miRNA sequence of miR-146a          | Disease susceptibility varies among different populations; regulates cytokine signaling and TLR pathways                                    | [25, 27]   |
| **Systemic lupus erythematosus (SLE)** |                            |                                               |                                                                                                                                             |            |
| miR-569                         | rs1057233 T (T/C)          | S51 3’-UTR                                    | High susceptibility to SLE                                                                                                                  | [28]       |
| miR-146a                        | rs50795329 G (G/A)         | Promoter of miR-146a primary transcript       | Associated with SLE                                                                                                                         | [29, 30, 34]|
| miR-146a                        | rs2436977 C (T/C)          | Intergenic region between PITG1 and miR-146a | Genetically associated with SLE in Europeans.                                                                                    | [31]       |
| miR-3148                        | rs3853839 G (G/C)          | TLR7 3’-UTR                                   | Increased risk for SLE                                                                                                                     | [32]       |
| **Congenital heart disease**    |                            |                                               |                                                                                                                                             |            |
| miR-196a2                       | rs1641913 C (T/C)          | Pre-miRNA region of miR-196a2                 | Increased risk                                                                                                                             | [24]       |
| **Hypertension (HT)**           |                            |                                               |                                                                                                                                             |            |
| miR-155                         | rs5186 C (A/C)             | AGTR1 3’-UTR                                  | Risk factor for HT and other CVDs                                                                                                           | [35, 36]   |
| miR-195 and -135                | rs9891870 (C/T)            | MRAS 3’-UTR                                   | Risk factor for HT and other CVDs                                                                                                           | [37]       |
| miR-31 and -584                 | rs7079 (C/A)               | AGT 3’-UTR                                    | Risk factor for HT                                                                                                                          | [38]       |
| **Coronary heart disease**      |                            |                                               |                                                                                                                                             |            |
| miR-149                         | rs4846049 G (G/T)          | MTHFR 3’-UTR                                  | Increased disease risk                                                                                                                     | [39]       |
| miR-149 precursor               | rs71428439 G (A/G)         |                                               | Affects miR-149 maturation and regulates Puma protein in apoptosis                                                                       | [40]       |
| **Dilated cardiomyopathy (DCM)**|                            |                                               |                                                                                                                                             |            |
| miR-196a2                       | rs1641913 T (C/T)          | Pre-miRNA region of miR-196a2                 | Increased disease risk                                                                                                                     | [41]       |
| miR-499                         | rs3746444 G (A/G)          | Pre-miRNA regions of hsa-miR-499              | Increased disease risk                                                                                                                     | [41]       |
DNA methylation was made during early 1980s with certain medications, such as hydralazine and procainamide inhibiting DNA methyltransferase (DNMT1) enzyme activity in CD4+ T cells [52], and was subsequently demonstrated by several studies [53, 54]. A variable expression of regulatory microRNAs in lupus CD4+ T cells due to epigenetics has been described [55]. Overexpression of several miRNAs, such as microRNAs in lupus CD4+ T cells due to epigenetic regulation has been demonstrated by several studies [53, 54]. A variable expression of regulatory CD4+ T cells [52], and was subsequently demonstrated by DNMT1 enzyme activity in medications, such as hydralazine and procainamide inhibiting DNMT1 way upstream of DNMT1 [56]. However, miR-148a and miR-126 directly inhibit DNMT1 expression via interaction with its 3'-UTR. Aberrant overexpression of miR-29b [58] and miR-126 [57] in lupus CD4+ T cells causes hypomethylation and overexpression of the methylation-sensitive genes CD11a and CD70, leading to T cell and B cell hyperactivity. Inhibition of such miRNAs expression in CD4+ T cells in patients with lupus caused reverse effects. Thus, the peculiar behavior of miRNAs could be potentially used as a prognostic biomarker for invasive phenotypes of inflammatory diseases.

Despite progress in the area of epigenetic modifications in other pathologies, the role of epigenetic factors affecting miRNA regulation in cardiac inflammatory diseases has still to be investigated. Possible differences among DNA methylation in cardiomyopathic and normal heart have been reported in humans [59] but due to lack of direct evidence the epigenetic regulation of miRNAs still remains elusive [60].

2. Role of miRNA in Fibrosis

The hallmark of fibrosis is tissue remodeling with excess deposition of extracellular matrix components, predominantly collagens. Recently, downregulation of miR-200 family (a–c) was reported in the lungs of mice with bleomycin-induced fibrosis; restoration of miR-200 expression reversed lung fibrosis via inhibiting TGF-β, suggesting its antifibrotic role [61]. Upregulation of another miRNA, miR-21, has been related to bleomycin-induced fibrosis (Figure 2). In this case, even the delayed administration of antisense nucleotides to block miR-21 was able to attenuate the profibrotic effect exerted by bleomycin [62–64]. Vettori et al. reviewed several studies and suggested putative miRNAs as implicated in fibrosis [65]. Amongst these, miRNAs with antifibrotic role in lungs include let-7d and miR-15b, -16, -26a/b, and -29; for heart they include miR-132, -133, and -590; however miR-17~92 cluster (miR-18a, 19a/b), -29a/b/c, and -30c are shared by both lung and heart. miRNAs with profibrotic role in lungs include miR-155, -199a/b, and -23a (clustered with -27a), in heart miR-208; miR-21 appeared in both lung and heart [65]. It has been speculated that targeting of deregulated miRNAs that are implicated in development of IPF, cardiac hypertrophy, and fibrosis may combat the progression of fibrosis in lung and heart.

3. Recent Developments in Role of miRNAs in Respiratory Inflammation and Cardiovascular Diseases

3.1. Role of miRNAs in Lung Inflammation. An inflammation/injury to lung tissue ignites an innate immune response. Immune cells including macrophages, monocytes, and neutrophils migrate into the lungs to protect the damaging cells and activate antimicrobial peptides and T-cell responses. It further activates proinflammatory response involving cytokines and chemokines, such as TNF-α, IFN-γ, CCL5/RANTES, IL-8, and IL-2 as well as innate immune response involving pathogen recognition receptors mediated activation of TLRs and their adaptor proteins such as TRIF, MYD88, TIRAP, and TRAM. These inflammatory stimulators provoke aberrant expression of miRNAs in several chronic inflammatory diseases; for example, miR-146a that targets COX2 gene is highly increased in response to the stimulation of inflammatory cytokines in several cell types from COPD patients [66], whereas it has reduced levels in CD4+ T- and CD8+ T-cells in patients with severe asthma [67]. A panel of miRNAs such as let-7a and miR-21, -155, -133a, -328, -1291, and -1248 has been shown to differentiate between healthy and inflamed lung in asthma. Additionally, differential expression of specific miRNAs (miR-1248 and -1291) characterized unique miRNA signatures among different types of chronic inflammation such as asthma and COPD [68]. Recently, Sessa and Hata in their review have suggested the role of miRNAs as possible diagnostic and prognostic tool in lung development and pulmonary diseases such as asthma, CF, COPD, IPF, and PAH. They also discussed the potential therapeutic targets for miRNAs using different molecular strategies [8]. Focusing on therapeutic application, Fujita et al. exclusively reviewed the RNA interference (RNAi) in lung inflammatory and cancer diseases along with therapeutic drugs under clinical trials, its route of administration, drug delivery agents, and target gene [69]. The status of miRNAs expression mentioned in this review has been reported to be valid using qRT-PCR or reporter gene assays in majority of the studies. These abnormal immune responses in response to environmental stimuli, infections, and aberrant genetic behavior including miRNA expression may lead to pathological processes and development of various pulmonary diseases [70]. In this review, focus will be made primarily on inflammatory pulmonary and cardiovascular diseases.

3.1.1. Asthma. Asthma is a chronic inflammatory lung disease stimulated by aberrant allergen-specific CD4+ T helper-2 (TH2) secreting cytokines, IL-2, -4, -5, -9, and -13 in response to various stimuli, such as allergens, infections, and air pollutants. It is characterized by elevated serum IgE, airway hyperresponsiveness, mucus hypersecretion, and eosinophil accumulation in the lung [73]. In asthma, upregulated miRNAs include let-7b and miR-21, -106a, -126, -145, -146a, -146b, -155, -181a, and -221, while the downregulated are let-7 family and miR-20b, -133a, -146a, -146b, and -28-5p (Table 3).

During the innate host response to allergens, miRNA expression with elemental regulatory signals has been linked...
Table 2: Role of miRNAs in epigenetic regulation of lung inflammatory diseases and cardiac remodeling.

| Disease and miRNA                     | Putative role in disease susceptibility                                                                 | References |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------|------------|
| Idiopathic pulmonary fibrosis (IPF)   | Hypermethylation and increased DNMT-1 expression: ↓ miR-17~92 in lung biopsies and lung fibroblasts from IPF patients | [71]       |
| miR-17~92 cluster                     |                                                                                                           |            |
| SLE                                   | Targets RASGRP1 and alters DNMT1 activity; DNA hypomethylation in disease state                             | [56]       |
| miR-21                                |                                                                                                           |            |
| miR-29b                               | Targets DNMT1; hypomethylation                                                                             | [58]       |
| miR-126                               | Inhibits DNMT1                                                                                            | [57]       |
| miR-148a                              | Inhibits DNMT1                                                                                            | [56]       |
| Myocardial infarction                 | Acetylation regulates miR-21 promoter in myocardial infarction                                            | [72]       |
| miR-21                                |                                                                                                           |            |

![Diagram](image_url)

**Figure 2:** Role of miRNAs in mechanism of fibrosis. The downregulation of miR-200 and -192 (inhibits epithelial-mesenchymal transition, EMT) and miR-29 (prevents the deposition of extracellular matrix, ECM) promotes fibrosis. Further, miR-21 amplifies TGF-β signaling and promotes myofibroblasts phenotype in fibrosis. This is characterized by increased cellular factors and expression of alpha-smooth muscle actin (α-SMA) and EDA-fibronectin.

to TLR signaling leading to activation of inflammatory pathways [27]. Notably, miR-21 is among the most overexpressed miRNAs in the inflamed lung tissue and in human airway epithelial cells in response to IL-13 treatment. It suppresses TLR-2 signaling in an animal model of asthma [74]. In a mouse model, it was shown that miR-126 expression was regulated by TLR4 or MyD88 deficient pathways and its antagonism suppressed the effector function of lung TH2 cells along with the development of allergic airways disease [75].

Also, for the bronchial smooth muscle cells, the reduction of miR-133a seems to increase bronchial hyperactivity in an animal model of asthma by increasing the expression of RhoA [76] (Table 3). Further, aberrant expression of miRNAs from primary bronchial epithelial cells including miR-152 family (miR-148a, -148b, and -152) that regulates plasma soluble human leukocyte antigen-G (sHLA-G) is associated with asthma [11, 15]. Recently, substantial differences were demonstrated in exosomal miRNAs profile including let-7.
(a–e) and miR-200 (-200b and -141) families between healthy subjects and patients with unprovoked, mild, and stable asthma [77].

3.1.2. Chronic Obstructive Pulmonary Disorder (COPD). Chronic obstructive pulmonary disease (COPD) is characterized by both chronic inflammation in the airway and systemic inflammation. It is due to combination of emphysema and chronic asthmatic bronchitis leading to impairment of lung function. However, the molecular mechanism of COPD has not been fully elucidated [78]. Proper diagnosis at early stages has remained a major challenge for COPD management. In this context, role of miRNA in COPD development and progression has been well illustrated in several studies (Table 3).

In COPD, miRNAs such as miR-146a and miR-155 have been demonstrated with a regulatory role in inflammation. Cytokine-stimulated prostaglandin E\(_2\) production and miR-146a expression in cultured fibroblasts correlated with clinical severity of COPD suggesting a pathogenic role of miR-146a [66]. A recent study evaluated the expression of 863 human miRNAs in blood cells of lung cancer and COPD patients along with healthy controls and identified 14 miRNAs as significant for comparing lung cancer and COPD patients [79]. Amongst these, eight miRNAs (hsa-miR-26a, -641, -383, -940, -662, -92a, -369-5p, and -636) were significant for differentiating COPD patients and healthy controls. The differentially expressed hsa-miR-26a acts as regulator of NF-\(\kappa\)B pathway by the regulation of its target gene, activating signal cointegrator 1 complex subunit 3 (ASCC3) [79]. San- fiorenzo et al. identified a six-plasma miRNA panel that was able to discriminate between NSCLC patients and COPD patients and an eleven-plasma miRNA panel that could distinguish non-small-cell lung carcinoma (NSCLC) patients from healthy subjects [80].

3.1.3. Cystic Fibrosis (CF). Cystic fibrosis (CF) is a mono- genetic disease caused by mutations in the CFTR gene and is characterized by mucus airway obstruction, neutrophil-dominated airway inflammation, and bacterial infection that lead to massive proinflammatory phenotype in the lung. The developmental processes, characterized by bronchial wall thickening and tissues fibrosis, are mediated by the production of reactive oxygen species and metalloproteases [8].

Role of miRNAs in CF has been reported by several works; among them, Oglesby et al. firstly described miR-126 in CF. In particular, miR-126 targets TOM1 protein, a negative regulator of IL-1\(\beta\), TNF-\(\alpha\), and LPS signaling pathway. The downregulation of miR-126 in CF patients correlated with upregulation of TOM1 and downregulation of NF-\(\kappa\)B-regulated IL-8 secretion [102]. Moreover, in human airway epithelial cells, three miRNAs, miR-384, -494, and -1246, were shown to inhibit CFTR and 3'UTR of Na\(^{+}\)-K\(^{+}\)-Cl\(^{-}\) cotransporter SLC12A2 which is important in regulating chloride transport [100]. Similarly, miR-101 and miR-494 were able to suppress CFTR activity by up to 80%, under in vitro study [101]. A higher level of miR-155 in CF through hypoxenation of cytokines, such as IL-8 in CF lung epithelial cells in in vitro [107,108] and in vivo models [106], suggests the role for miRNA in CF pathogenesis. Furthermore, to understand the aberrant expression mechanism of miR-155 in CF, two mRNA destabilizing inflammatory RNA-binding proteins, KSRP and TTP, were shown to have an antagonistic role in miR-155 biogenesis [109]. Regarding the biosynthesis of CFTR, miR-138 was shown to alter the expression of several encoding genes associated with CFTR and it also regulates CFTR expression through its interactions with the transcriptional regulatory protein SIN3A [103]. Recently, high expression of miR-101, -144, -145, -215, -223, -509-3p, and -494 in CF cells was shown to be as dynamic regulators of CFTR [98,104,105,108,110].

3.1.4. Idiopathic Pulmonary Fibrosis (IPF). Idiopathic pulmonary fibrosis (IPF), defined as a specific form of chronic, progressive fibrosing interstitial pneumonia of unknown cause which is associated with the histopathologic and/or radiologic pattern of usual interstitial pneumonia (UIP) [135], has the largest epidemiological impact and the worst prognosis among interstitial lung disease. Approximately 10% of the microRNAs are significantly deregulated in IPF lungs [III].

In IPF, the regulation of epithelial-mesenchymal transition (EMT) through inhibition of let-7 family members by transforming growth factor \(\beta\)1 (TGF-\(\beta\)1) and a high expression of HMGA2 in alveolar epithelial cells were demonstrated both in vitro and in vivo [III]. Related to progression of fibrosis through myofibroblast differentiation, a high expression of miR-21 was shown in the lungs of bleomycin-treated mice as well as IPF patients and its inhibition reduced the severity of fibrosis [62]. In addition, miR-29 was shown to be involved in EMT and target profibrotic genes in human fetal lung fibroblasts [II6] and in bleomycin-induced pulmonary fibrosis in mice [II7]. Recently, miR-21 and miR-155 expressions were shown as detectable and stable in serum of patients with IPF [64]. Interestingly, miR-200 family members were shown to reverse the fibrogenic activity of pulmonary fibroblasts in IPF [61]. Comparative analysis of miRNA and gene expression microarray data in IPF revealed enrichment of the TGF\(\beta\)1, Wnt, Sonic Hedgehog, p53, and VEGF pathways and complex regulatory networks [II6]. In addition, pathway analysis indicated that altered microRNA expression may be associated with HGF signaling, cholecystokinin/gastrin-mediated signaling, and IGF-1 signaling, among others, in fibrotic lung disease [63].

3.1.5. Other Inflammatory Lung Diseases. Despite the critical role of miRNA in inflammatory response, limited studies have focused on its role in inflammation-induced acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) [122]. The roles of miRNAs such as Let-7a and miR-21, -32, -127, -146a, -155, -181b, -466-5p, and -466-3p have been suggested to be involved in this severe pathology (Table 3). However, the knowledge of this condition has remained limited to establish their role as biomarker for early prevention, prognosis, and therapeutics role in possible therapy; the roles

Mediators of Inflammation
| miRNA          | Cell/tissue/body fluid (models) | miRNA regulation; validation method | Predicted target gene/possible effect                                                                 | References |
|---------------|--------------------------------|------------------------------------|-------------------------------------------------------------------------------------------------------|------------|
| Asthma        |                                 |                                    |                                                                                                       |            |
| let-7 family  | A549 cells and primary cultured T-cells (C) | Down; qRT-PCR, northern blotting | 3'-UTR of IL-13                                                                                         | [81]       |
| let-7 (a-e) and miR-200 (200b, and 14l) families Exosomes from BALF (H) | Differentially expressed; microarray, qRT-PCR | let-7 is associated with IL-13; miR-200 regulate EMT                                                      | [77]       |
| miR-20b       | Alveolar macrophages (M)         | Down; qRT-PCR, transfection assay  | ↓miR-20b: ↑VEGF                                                                                       | [82]       |
| miR-21        | Whole lung, macrophage, dendritic cells (M) | Up; microarray, qRT-PCR, ISH       | IL-12p35                                                                                              | [74, 83]   |
| miR-106a      | Mouse macrophage (M), Jurkat (T-cell), Raji (B-cell), THP-1 cells (C) | Up; qRT-PCR, northern blotting | IL-10; mmu-miR-106a: ↑IL-10, ↓asthma features                                                         | [84, 85]   |
| miR-126       | Lower airway tissue (M)          | Up; microarray, qRT-PCR            | OBF.1                                                                                                | [75, 86]   |
| miR-133a      | Bronchial smooth muscle cells and bronchial tissues of mouse (C + M) | Down; qRT-PCR                       | ↓miR-133a: ↑RhoA                                                                                                | [76]       |
| miR-145, -21, and let-7b Lower airway tissue (M) | Up; qRT-PCR          | ↓miR-145: ↓T_{H2} cytokine (IL-13, IL-5, IFN-γ) production                                              | [87]       |
| miR-146a, -146b, and -28-5p Human circulating T cells (H + C) | Down; microarray, qRT-PCR | Involved in T-cell activation                                                                          | [67]       |
| miR-146a, -146b, and -181a Spleen CD4+ T lymphocytes (M) | Up; qRT-PCR            | Th2 inflammation; proinflammatory factors in asthma                                                   | [88]       |
| miR-155       | Cell line and macrophages (C + M) | Up; microarray, qRT-PCR, transfection assay | ↓miR-20b: ↑Glucocorticoids                                                                                   | [89]       |
| miR-221       | Mice mast cell line (M + C), ASM cells cultured from bronchial biopsies (C + H) | Up; qRT-PCR, transfection assay | Augment cell proliferation and IL-6 production                                                           | [90, 91]   |
### Table 3: Continued.

| miRNA | Cell/tissue/body fluid (models) | miRNA regulation; validation method | Predicted target gene/possible effect | References |
|-------|---------------------------------|------------------------------------|--------------------------------------|------------|
| let-7c and miR-125b | Induced sputum (H) | Down; qRT-PCR | ↓let-7c; ↑TNFR-II | [92] |
| miR-1 (muscle specific) | Muscle biopsy (H) | Down; qRT-PCR | IGF-1, HDAC4; ↓miR-1; ↓MRTF-SRF axis | [93] |
| miR-1, -499, -133, and -206 | Plasma (H) | Up in patient with stable COPD; qRT-PCR | miR-499 with markers of inflammation NF-κB p50 | [94] |
| miR-7 | Serum (H) | Up; qRT-PCR | ↓ | [95] |
| miR-15/107 family (miR-15b, -424, and -107), -223, and -127a | Lung tissue (H) | Up; microarray, qRT-PCR, ISH, and transfection assay | ↓ | [96] |
| miR-18a and -365 | Cell line, Lung tissue (C + H) | Up; microarray, qRT-PCR, ISH, and transfection assay | — | [96, 97] |
| miR-20a, -28-3p, -34c-5p, and -100 | Serum (H) | Down; qRT-PCR | — | [95] |
| miR-26b, -29b, -101, -105b, -133b, -152, -483-5p, -532-5p, and -629 | Plasma (H) | Down; qRT-PCR | ↓miR-106b level negatively correlates with disease progression | [78] |
| miR-101 and -144 | Human bronchial epithelial cell line (H + C), mice lung (C + M) | Up; qRT-PCR, luciferase assay, ISH | ↑miR-101; ↓CFTR; ↓COPD | [98] |
| miR-146a | Primary lung fibroblasts (C + H) | Up; microarray, qRT-PCR | Degradation of COX-2 mRNA | [66] |
| miR-452 | Alveolar macrophages (H) | Down; microarray and qRT-PCR | ↓miR-452; ↓MMP12 | [99] |
| miR-923 and -937 | Lung tissue (H) | Down; microarray | Most downregulated in COPD | [96] |
| Cystic fibrosis (CF) | Several cell lines (C) | Up; qRT-PCR and luciferase assay | CFTR 3′-UTR | [100] |
| miR-14 and -494 | HEK293 cell line (C) | Up; luciferase assays | ↓CFTR | [101] |
| miR-101, -494 | Human bronchial epithelial cell line, mice lung (C + M) | Up; qRT-PCR, luciferase assay, and ISH | ↓miR-101; ↓CFTR; ↓COPD | [98] |
| miR-126 | Bronchial epithelial cell line (C) | Down; qRT-PCR and luciferase assay | ↓miR-126; ↑TOM1, TOLLIP | [102] |
| miR-138 | Primary human airway epithelial cells (H + C) | Up; qRT-PCR and luciferase assay | Regulate CFTR | [103] |
| miR-145, -223, and -494 | In vivo bronchial brushings and cell lines (H + C) | Up; qRT-PCR and luciferase assay | Regulate CFTR | [104] |
| miR-145 and -494 | Nasal epithelial tissues (H) | Up; qRT-PCR | ↓miR-145; ↓SAMD3; ↓miR-494; ↓CFTR | [105] |
| miR-155 | Cell line, mouse (C + M) | Up; microarray and qRT-PCR | FGF7/KGF; ↑miR-155; ↓SHIP1, ↑IL-8 | [106–109] |
| miR-215 | Ex vivo CF lung epithelial cells (C) | Up; qRT-PCR | ↑IL-8 | [108] |
| miR-384, -494, and -1246 | Airway epithelial cells (C) | Down; qRT-PCR and luciferase assay | 3′-UTR of SLC12A2; ↓CFTR | [100] |
| miR-509-3p and -494 | Primary human airway epithelial cells (H + C) | Up; qRT-PCR | Regulate CFTR expression | [110] |
| miRNA | Cell/tissue/body fluid (models) | miRNA regulation; validation method | Predicted target gene/possible effect | References |
|-------|--------------------------------|------------------------------------|---------------------------------------|------------|
| Idiopathic pulmonary fibrosis (IPF) | Let-7d, miR-26, and miR-30 family | Lung biopsies and lung epithelial cells (M + C) | Down; microarray, qRT-PCR, and luciferase assay | ↓let-7d: ↑HMGA2 | [111] |
|       | miR-17~92 cluster               | Lung biopsies (H)                  | Down; microarray and qRT-PCR          | ↑TGF-β1; ↓SMAD7; enhance EMT and IPF | [62–64, 114] |
|       | miR-21                          | Lung biopsies and serum (M + H)    | Up; microarray, qRT-PCR, ISH, and luciferase assay | ↑TGF-β, ↓SMAD7; enhance EMT and IPF | [112, 113] |
|       | miR-29                          | Lung tissues and pulmonary fibroblasts (M + C) | Down; microarray, qRT-PCR, ISH, and luciferase assay | Integrin, alpha 11; ADAMTS9; ADAM12, and nidogen-1 | [115–117] |
|       | miR-34a                         | Lung (M)                           | Up; microarray, qRT-PCR, ISH, and luciferase assay | —           | [63] |
|       | miR-154, -134, -299–5p, -410, -382, -409–3p, -487b, -31, and -127 | Lung tissue + primary normal human lung fibroblast cells (H + C) | Up; microarray and qRT-PCR | SMAD3 to promoter of miR-154 | [118] |
|       | miR-200 family (a-c)            | Lung (M)                           | Down                                  | Inhibit TGF-β1 induced EMT of alveolar epithelial cells | [61] |
| Acute lung injury (ALI) and inflammation | miR-127                          | Mouse macrophage cell line (M + C)   | Down; luciferase assay and microarray | IgG FcγRI (CD64); ↑miR-127; cytokine from macrophages | [119] |
|       | Let-7; miR-21; -146; -155       | Lung (M)                           | Up; TaqMan low density arrays and qRT-PCR | Let-7 regulates IL-6; miR-146 -SMAD-4; miR-155 – SOCS-1 | [120] |
|       | miR-32*, -466-5p; -466-3p       | Rat alveolar epithelial cell (R)    | Up; microarray and qRT-PCR            | —           | [121] |
|       | miR-146a                        | Lung, macrophage cell line (R + C) | Up                                    | ↑miR-146a: ↓TNF-α, IL-6, IL-1β, IRAK-1, TRAF-6; ↑miR-181b: ↑Importin-α3; regulate NF-κB signaling | [122, 123] |
|       | miR-181b                        | Cell line (C)                      | Up; microarray and qRT-PCR            | —           | [124] |
| miRNA                      | Cell/tissue/body fluid (models) | miRNA regulation; validation method | Predicted target gene/possible effect                                                                 | References |
|----------------------------|---------------------------------|------------------------------------|--------------------------------------------------------------------------------------------------------|------------|
| **Pulmonary arterial hypertension (PAH)** |                                 |                                    |                                                                                                         |            |
| miR-17/92 cluster (miR-17-5p, -20a) | hPAECs (H + C)                  | Up; qRT-PCR; reporter gene assay   | ↑miR-17/92; ↓BMPR2 protein; ↑STAT3 (TGF-β)                                                            | [125]      |
| miR-21                     | hPASMC (H + C)                  | Up; qRT-PCR and western blotting   | ↑miR-21; ↓(PDC4, SPRY2, PPARα, BMPR2); role in cell proliferation and migration                         | [126, 127] |
| miR-23b, -130a, and -191   | Blood buffy coat (H)            | Up; qRT-PCR                        | miR-23b: ↓BMPR1b; miR-130a: ↓BMPR1b, SMAD2; ↑PDC4, SPRY2, PPARα, BMPR2; role in cell proliferation and migration | [128]      |
| miR-124                    | hPASMC (H + C)                  | Down; qRT-PCR                      | NFATc1, CAMTA1 and PTBPI; inhibitor of NFAT signaling                                                 | [129]      |
| miR-145                    | hPASMC (H + C) and mouse (M)    | Up; qRT-PCR                        | ↑miR-145; BMPR2 mutations; vessel remodeling                                                          | [130]      |
| miR-204                    | hPASMC (H + C), mouse (M), and rat lung (R) | Down; qRT-PCR | ↑STAT3, ↓SHP2; accounts for the proliferative and antiapoptotic phenotypes                             | [131]      |
| miR-206                    | Lung tissue + hPASMC (H + C) and mouse (M) | Down; qRT-PCR | ↑Notch-3, ↑HIF-1α/Fhl-1 pathway; regulate proliferation                                              | [132, 133] |
| miR-424 and 503            | hPAECs (H + C), mouse (M) and rat (R) lung endothelial cell (C) | Down; qRT-PCR | ↑FGFR1, FGF2; antiproliferative effects                                                              | [134]      |
| miR-451 and -1246          | Blood (H)                       | Down; qRT-PCR                      |↑miR-206: Titin; miR-1246: caveolin1, GSK3β, and cadherin2                                                | [128]      |

↑: increased level; ↓: decreased level; ⊥: inhibition. Investigating models: mouse (M), rat (R), cell culture (C), and human (H). ADAM metalloproteinase with thrombospondin type I motif, 9 (ADAMTS9); bone morphogenic protein receptor type I b (BMPR1b); epithelial-mesenchymal transition (EMT); fibroblast growth factor 2 (FGF2); fibroblast growth factor receptor 1 (FGFR1); human pulmonary arterial endothelial cells (HPAECs); in situ hybridization (ISH); insulin-like growth factor 1 (IGF-1); interleukin-1 receptor-associated kinase 1 (IRAK1); interleukin-8 (IL-8); histone deacetylase 4 (HDAC4); matrix metalloproteinase-12 (MMP-12); nuclear factor κ-B (NFκB); nuclear factor of activated T cells (NFAT); peroxisome proliferator-activated receptor-α (PPARα); POU domain class 2 associating factor 1, also named Oct binding factor 1 (OBE1); programmed cell death protein 4 (PDC4); pulmonary artery endothelial cells (PAECS); human pulmonary artery smooth muscle cells (hPASMCs); human pulmonary arterial endothelial cells (HPAECs); quantitative real-time PCR (qRT-PCR); signal transducer and activator of transcription 3 (STAT3); solute carrier family 12 (sodium/potassium/chloride transporters), member 2 (SLC12A2); sprouty 2 (SPRY2); suppressor of cytokine signaling proteins (SOCS); target of Myb (TOM1); Toll-interacting protein (TOLLIP); TNF receptor associated factors (TRAFs); transforming growth factor beta (TGF-β); tumor necrosis factor receptor type II (TNFR-II); vascular endothelial growth factor (VEGF).
of miRNAs mentioned above are also needed to be validated and confirmed by more studies.

3.1.6. Pulmonary Artery Hypertension (PAH). Pulmonary arterial hypertension (PAH) is a disease of the pulmonary vasculature characteristic by vascular remodeling associated with obliteration of pulmonary arterioles and formation of plexiform lesions composed of hyperproliferative endothelial and vascular smooth-muscle cells [134]. Wei et al. identified a spectrum of downregulated (miR-451 and -1246) and upregulated (miR-23b, -130a, and -191) miRNAs in PAH patients, suggesting these circulating miRNAs as potential biomarker for early disease detection [128]. Besides, several miRNAs (miR7/92 cluster, -21, -23b, -130a, and -145) detected in PAH were reported to be connected with disrupted BMPR2 pathway in PAH (Table 3). Sarkar et al. confirmed the role of miR-21 in smooth muscle cell proliferation and migration with increased expression of miR-21 in pulmonary artery smooth muscle cells (PASMCs) [126]. By contrast, miR-204 expression in PASMCs was downregulated in both human and rodent PAH model, and delivery of the synthetic miR-204 significantly reduced disease severity in animal model [131]. Similarly, in vivo administration of miR-21, -424, and -503 ameliorated PAH [134, 136]. Collectively, these observations propose reestablishment of normal miRNA level as a potential therapeutic approach.

3.2. Role of miRNAs in Cardiac Remodeling. Inflammation plays a key role in cardiac function and remodeling during progression of cardiovascular diseases (CVDs). Biological processes affecting fibroblasts, extracellular matrix proteins, coronary vasculature, cardiac myocytes, and ion channels are involved in this remodeling process [137, 138]. The vascular cell adhesion molecule-1 (VCAM-1) expression is induced through NF-κB mediated pathway and proinflammatory cytokines such as IL-β, IL-6, and TNF-α. The VCAM-1 as well as chemokine receptor-2 (CCR2) induces the interaction of vascular endothelial cells (ECs) with monocytes and T lymphocytes which triggers the early atherosclerotic plaques [139, 140]. At transcriptional level, understanding of miRNAs biological functions in the cardiovascular system in physiological and pathological condition is considered to be potentially crucial for CVD prevention, diagnosis, and therapy [138, 141]. For miRNA profiling of cardiac remodeling in response to inflammation, serum based extracellular miRNAs have been extensively utilized as noninvasive and reliable diagnostic tool (Table 4). The pathological process of the myocardium is associated with an altered expression profile of genes that are important for cardiac function. Regulation of cardiac gene expression is complex, with individual genes being controlled by multiple enhancers that regulate specific expression patterns in the heart. Increasing evidences indicate that miRNAs play important role in myocardial pathology adding a new point of view of how cardiac gene expression is regulated.

Recent reviews provide an overview of specific miRNA signatures with dysregulated level in CVDs [138]. These are transported as extracellular microRNAs during cell-to-cell RNA communication and considered as important diagnostic markers [179, 193–195]. For example, Small and Olson explored the role of miRNAs in heart development and pathological cardiac remodeling along with their potential therapeutic targets. They also suggested exciting possibilities for the therapeutic manipulation of miRNA-regulated processes in several cellular mediated diseases that are difficult to modulate therapeutically [196]. Further, extending this approach for therapeutic inhibition of cardiovascular miRNAs, van Rooij and Olson summarized the current chemistries (tiny LNA, LNA-DNA miximer, antagonim, and 2’-F-2’-MOE miximer) for targeting miRNAs [197]. In a study, significant increase in serum level of miR-1 and -133 in patients with cardiovascular diseases such as acute myocardial infarction, unstable angina pectoris, and cardiomyopathy indicated its implication in myocardial damage [198]. In particular, specific set of miRNAs is involved in atherosclerosis, myocardial infarction, heart failure, myocardial hypertrophy, and fibrosis. Here, we summarize and highlight some of the most investigated miRNAs in this field (Table 4), focusing on the main groups of miRNAs involved in myocardial remodeling.

3.2.1. Atherosclerosis. Atherosclerosis (AS), a chronic inflammatory disease affecting major arteries, represents one of the causes of myocardial infarction, ischemic stroke, and peripheral artery disease [199]. miRNAs, such as miR-21, -146a, and -155, are involved in most of the inflammatory diseases [142] and have been implicated in the development of AS; for example, miR-21, -34a, -146a, -146b-5p, and -210 were significantly upregulated in vulnerable atherosclerotic plaques [143] (Table 4). While miR-155 was shown to promote AS by repressing B66 in macrophages, its inhibition reduced the expression of CCL2, which recruits monocytes to atherosclerotic plaques [200]. Mechanistically, miR-155 (proinflammatory) and miR-146 (anti-inflammatory) were reported to regulate dendritic cell functions in atherosclerotic inflammation [201]. As far as the functional aspects of this process, miR-155 is upregulated by macrophage-derived miR-342-5p through Akt-1 inhibition, which results in stimulation of inflammatory mediators such as Nos2 and IL6 in macrophages [202]. On adverse, miR-155 was also suggested to possess protective feature as it prevented development of AS and its progression by regulating inflammatory response and MAP3K10 of MAPK pathway [203]. This contrasting effect of miR-155 may be context dependent and differ between early and advanced stages [204]. Other miRNAs implicated in AS, for example, miR-27 [201] or miR-214, were shown to possess cardioprotective effects against ischemic injury in mouse model by controlling excessive calcium influx and cell death [205].

Also, suppression of NF-κB signaling and inhibition of atherosclerotic lesion by systemic delivery of miR-181b in apolipoprotein E-deficient mouse model with reduced expression of miR-181b suggested the protective role for AS [146]. The two different miRNAs from different sources
### Table 4: miRNAs in cardiovascular diseases.

| miRNA          | Cell/tissue/body fluid (models)                                                                 | Regulation | Validation method | Predicted target gene/possible effect                                                                 | References |
|----------------|-----------------------------------------------------------------------------------------------|------------|-------------------|--------------------------------------------------------------------------------------------------------|------------|
| **Atherosclerosis** |                                                                                                 |            |                   |                                                                                                        |            |
| miR-21         | Plaques and arteries (H)                                                                      | Up         | qRT-PCR           | Signal transduction; regulation of transcription; vesicular transport                                   | [142, 143]|
| miR-26,-30, and -125a | Plaque tissue (H)                                                                     | Up         | qRT-PCR           | Signal transduction; regulation of transcription; vesicular transport                                   | [144]      |
| miR-34a        | Plaques and arteries (H)                                                                      | Up         | qRT-PCR           | Signal transduction; regulation of transcription; vesicular transport                                   | [143]      |
| miR-146a       | Plaques and arteries (H)                                                                      | Up         | qRT-PCR           | Signal transduction; regulation of transcription; vesicular transport                                   | [142, 143, 145] |
| miR-146b-5p    | Plaques and arteries (H)                                                                      | Up         | qRT-PCR           | Signal transduction; regulation of transcription; vesicular transport                                   | [143]      |
| miR-181b       | Aortic intima (M) and plasma (H)                                                               | Down       | qRT-PCR           | Importin-α3; ↓NF-κB signalling and atherosclerotic lesion formation                                   | [146]      |
| miR-210        | Mouse arterial endothelial cell (M+C)                                                         | Up         | qRT-PCR           | Potential biomarker                                                                                   | [143]      |
| miR-712        |                                                                                                 |            |                   |                                                                                                        |            |
| **Acute myocardial infarction (AMI)** |                                                                                                 |            |                   |                                                                                                        |            |
| Let-7b         | Plasma (H)                                                                                    | Up         | qRT-PCR           | Differentiate AMI patients from healthy controls                                                      | [148]      |
| miR-1          | Plasma (H), serum (M), and rat cardiac cells (R+C)                                            | Up         | qRT-PCR           | Potential biomarker for AMI                                                                            | [149–154] |
| miR-21         | Heart (R)                                                                                    | Down       | qRT-PCR           | Expression signature in early phase of AMI                                                            | [155]      |
| miR-30a and -195 | Plasma (H)                                                                                   | Down       | qRT-PCR           | Differentiate AMI patients from healthy controls                                                      | [148]      |
| miR-122        | Plasma (H)                                                                                    | Down       | qRT-PCR           | Potential biomarker for AMI                                                                            | [151, 156] |
| miR-133a and -b | Plasma and whole blood (H)                                                                  | Up         | qRT-PCR           | Potential biomarker for AMI                                                                            | [150, 151, 154, 156] |
| miR-133 and -328 | Plasma and whole blood (H)                                                                 | Up         | qRT-PCR           | Potential biomarker for AMI                                                                            | [157]      |
| miR-126        | Plasma (H)                                                                                    | Down       | qRT-PCR           | Potential biomarker for AMI                                                                            | [153]      |
| miR-155        | Monocytes, B-cells, T-cells (H), and knockout mice (M)                                       | Up         | miRNA profiling and qRT-PCR | TLR- pathway, NF-κB, FADD, Rip-1; proinflammatory miRNA                                              | [158]      |
| miR-208a and -499 | Plasma (H)                                                                                   | Up         | qRT-PCR           | Potential biomarker for AMI                                                                            | [154, 159, 160] |
| miRNA | Cell/tissue/body fluid (models) | Regulation | Validation method | Predicted target gene/possible effect | References |
|-------|-------------------------------|------------|-------------------|--------------------------------------|------------|
| **Cardiac hypertrophy** | Heart and skeletal muscle (M + R) and coronary artery cells (H) | Down | Northern blot; qRT-PCR | Twinfilin-2 | [161] |
| miR-1 | Heart (M) | Up | Northern blot and qRT-PCR | — | [162] |
| miR-21 | Cardiac and muscle specific (M) | Up | qRT-PCR and western blot | Sirt1 and HDACY | [163] |
| miR-22 | Cardiomyocytes (M) | Up | Western blot and qRT-PCR | PPAR-γ | [164] |
| miR-27b | Plasma (H) | Up | qRT-PCR | | [165] |
| miR-29a | Cardiac fibroblast (H), cardiac tissue, and plasma (H) | Down | qRT-PCR | | [166] |
| miR-30 | Human (H), mouse (M), and rat (R) heart | Down | qRT-PCR and northern and western blot | Beclin-1; ↑Ang II; ↑miR-30a; ↑Beclin-1; excessive autophagy; myocardial hypertrophy | [167,168] |
| miR-133 | Leukocytes (M) | Up | — | Promotes cardiac inflammation, hypertrophy, and failure | [169] |
| miR-155 | Heart and cardiomyocytes (R) | Up | Luciferase assay and western blot | ↑miR-214; ↓EZH2 | [136] |
| **Cardiac fibrosis** | Cardiac fibroblast (H) | Up | — | SPRY1 | [170] |
| miR-21 | Cardiac myocytes (M) | Up | qRT-PCR | ↓PTEN; protects against cardiac ischemia/reperfusion injury | [171,172] |
| miR-29 | Cells, mouse (M), and human (H) cardiac tissue | Up | miRNA microarray and qRT-PCR | Inflammatory cytokines | [173] |
| miR-133 | Heart (M) | Down | qRT-PCR | Coll1A1 | [170,174] |
| miR-26a | Heart (H) | Down | qRT-PCR | CTGF and Coll1A1 | [175] |
| miR-30 | Heart (H + R), cardiac fibroblast, and myocytes (R + C) | Up | qRT-PCR | ↑miR-30; ↓CTGF | [176] |
| miR-122 | Endomyocardial biopsies (H) | Down | qRT-PCR | ↓TGF-β1; progression of myocardial fibrosis in aortic stenosis | [177] |
| miRNA | Cell/tissue/body fluid (models) | Regulation | Validation method | Predicted target gene/possible effect | References |
|-------|---------------------------------|------------|-------------------|--------------------------------------|------------|
| miR-17/92a cluster, -126, -145, and -155 | Plasma (H) | Down | qRT-PCR | Potential biomarker for CAD | [178] |
| miR-21 | Endothelial cells and vessel wall (H) | Up | qRT-PCR | Potential biomarker for CAD | [179] |
| miR-106b/25 cluster, -17/92a cluster, -21/590-5p family, -126*, and -451 | Plasma (H) | Up | qRT-PCR | May affect inflammation, hypoxia, angiogenesis, apoptosis, and extracellular matrix (ECM) degradation | [180] |
| miR-126 | Endothelial cells and vessel wall (H) | Down | qRT-PCR | Potential biomarker for CAD | [151, 179] |
| miR-133a | Endothelial cells and vessel wall (H) | Up | qRT-PCR | Potential biomarker for CAD | [179] |
| miR-135a | PBMC (H) | Up | qRT-PCR | Potential biomarker for CAD | [181] |
| miR-147 | PBMC (H) | Down | qRT-PCR | Potential biomarker for CAD | [181] |
| miR-155 | Endothelial cells and vessel wall (H) | Down | qRT-PCR | Potential biomarker for CAD | [151, 179] |
| miR-208a | Endothelial cells and vessel wall (H) | Up | qRT-PCR | Potential biomarker for CAD | [151] |
| miR-221 | Endothelial cells and vessel wall (H) | Down | qRT-PCR | Potential biomarker for CAD | [179] |
| miR-370 | Endothelial cells and vessel wall (H) | Up | qRT-PCR | Potential biomarker for CAD | [179] |
Table 4: Continued.

| miRNA | Cell/tissue/body fluid (models) | Regulation | Validation method | Predicted target gene/possible effect | References |
|-------|--------------------------------|------------|------------------|--------------------------------------|------------|
| Heart failure | | | | | |
| miR-1 | Muscle (H) | Down | qRT-PCR | GATA H and MEF2A | [182–184] |
| miR-16, -20b, -93, -106b, -223, and -423-5p | Plasma (R) | Up | qRT-PCR | Expression level changes during progression of hypertension-induced heart disease | [185] |
| miR-21 | Plasma, muscle, and heart tissue (H) | Up | qRT-PCR | PTEN | [182–184] |
| miR-23a | Plasma, muscle, and heart tissue (H) | Up | qRT-PCR | MuRF1 | [182–184] |
| miR-29b | Plasma, muscle, and heart tissue (H) | Down | qRT-PCR | Col1A1, Col1A2, and Col3A1 | [182–184] |
| miR-30 | Plasma, muscle, and heart tissue (H) | Down | qRT-PCR | CTGF | [176, 182–184] |
| miR-125 | Plasma, muscle, and heart tissue (H) | Up | qRT-PCR | — | [182–184] |
| miR-126 | Plasma (H) | Down | qRT-PCR | Useful biomarker for heart failure | [186] |
| miR-133 | Right atrial appendages (H) | Down | qRT-PCR | CTGF and SRF | [187] |
| miR-208a | Cardiac tissue and plasma (M + R), Plasma (M + H), H9c2 (C), and mononuclear cells (M + H) | Microarray profiling; qRT-PCR | | | [188] |
| miR-210 | Plasma (H) and serum (H) | Up | qRT-PCR | Repress ISCU, leading to repression of mitochondrial respiration | [189] |

↑: increased level; ↓: decreased level; ⊥: inhibition. Investigating models: mouse (M), rat (R), cell culture (C), and human (H). A disintegrin and metalloproteinases (ADAMs); collagen, type I, alpha 2 (Col1A2); collagen, type II, alpha 1 (Col2A1); connective tissue growth factor (CTGF); cytoplasmic SH2 domain containing protein tyrosine phosphatase (SHP2); enhancer of zeste homolog 2 (EZH2); Fas-associated death domain (FADD); iron-sulfur cluster assembly protein (ISCU); matrix metalloproteinases (MMPs); myocyte enhancer factor 2A (MEF2A); muscle ring-finger protein-1 (MuRF1); nuclear factor-kB (NF-kB); phosphatase and tensin homolog (PTEN); receptor-interacting protein 1 (RIP1); serum response factor (SRF); sirtuin 1 (Sirt1); proliferator-activated-receptor-γ (PPAR-γ); sprouty homolog 1 (SPRY1); Toll-like receptor (TLR); tissue inhibitor of metalloproteinase 3 (TIMP3).
Mediators of Inflammation 17

Downregulation of miR-133 could promote fibrosis by fibrosis observed in angiotensin II-dependent hypertension represents the main collagen fibres involved in myocardial hypertrophy in both myocardial hypertrophy and fibrosis observed in experimental model of angiotensin II-dependent hypertrophy. MiR-29 family was also related to cardiac fibrosis. Kin et al. found upregulated miR-29 in abdominal aortic aneurysm [173] (Table 4), and van Rooij et al. observed dramatically downregulated miR-29 in the region of fibrotic scar after acute myocardial infarction [210]. Another miRNA, miR-30, regulates a key profibrotic protein, connective tissue growth factor (CTGF) which contributes to collagen synthesis. It downregulates CTGF level and thus controls structural changes in the myocardium extracellular matrix [176]. Similarly, another target of miR-30, beclin-1 (an autophagy-related gene), also exhibited an inverse relationship. The overexpression of beclin-1 gene promotes Angiotensin II-induced myocardial hypertrophy by downregulation of miR-30 in cardiomyocytes through excessive autophagy [166].

3.2.4. Heart Failure. The pathogenesis and clinical manifestations of heart failure are complex and involve disruption of normal mechanisms that regulate cardiomyocyte gene expression, growth, survival, and function. Cardiac interstitial cells and vascular cell also actively participate in disease process, resulting in altered myocyte-nonmyocyte signalling, cardiac fibrosis, and decreased vascular density. Currently only B-type natriuretic peptide (BNP) and pro-brain natriuretic peptide (NT-proBNP) are clinically established diagnostic biomarkers for heart failure. However, evaluation of HF progression along with the appropriate timing for therapeutic interventions in the HF patient is important from the perspective of clinical management [185] and new markers are therefore needed.

In this context, signature expression patterns of specific miRNAs that are consistently aberrantly expressed in heart failure patients were described: miR-1, -29, -30, -126, and -133 are found to be downregulated in heart failure patients, whereas miR-21, -23a, -25, -210, -195, and -423-5p are among the upregulated [182–184]. Further, circulating levels of plasma miR-16, -20b, -93, -106b, -223, and -423-5p were significantly increased during hypertension-induced heart failure in mouse model [185]. Plasma concentration of miR-423-5p was significantly elevated in heart failure patients due to dilated cardiomyopathy (DCM) and positively correlated with NT-proBNP level [190]. In a recent study, biopsy of the right atrial myocardium tissue from 83 patients revealed enrichment of miR-1 and miR-133 within cardiac muscle and the decreased level of miR-133a was associated with signs of heart failure [187].

Among several miRNAs, miR-21 was implicated in several cardiac remodelling issues (Table 4). It is expressed in all characteristic cardiovascular cell types, including vascular smooth muscle cells, endothelial cells, cardiomyocytes, and cardiac fibroblasts, and target genes such as programmed cell death 4 (PDCD4), phosphatase and tensin homology deleted from chromosome 10 (PTEN), sprouty1 (SPRY1), and sprouty2 (SPRY2) involved in proliferative vascular disease [211]. Reports indicate miR-21 to be involved in pathogenesis of in vitro cardiomyocyte hypertrophy and indirectly in vivo via fibroblasts. In contrast, some studies report an antihypertrophic effect of miR-21 in isolated cardiomyocytes, a reduction in infarct size by miR-21, or an inhibition of H2O2-induced apoptosis of isolated cardiomyocytes [212]. Also, miR-21 exhibits a protective role by reducing myocyte apoptosis and ischemic heart failure/reperfusion injury through suppression of phosphatase and tensin homolog (PTEN), a negative regulator of the AKT pathway [171,172].
to its role in both pro- and antihypertrophic, the role of miR-21 in cardiac disease remains controversial. The reasons for the discrepancy between these studies are unclear; however, miR-21 is expressed predominantly in cardiac fibroblasts, not cardiomyocytes [170, 212], primarily due to comparatively increase in the number of cardiac fibroblast cells. Overall, it is indicated that miR-21 inhibits endothelial cell proliferation and migration, whereas it promotes cardiomyocyte and fibroblast survival upon myocardial ischaemia/reperfusion. The potential role of miR-21 in cardiac fibrosis and hypertrophy is still debated and measures such as global knockdown or overexpression of miR-21 in the reperfused myocardium are suggestive to provide an insight on postinfarct remodeling [212].

4. miRNA as Biomarker

Aberrant miRNA expression has been associated with various human diseases and its determination can differentiate between normal and diseased tissue [213]. Besides cancer, altered miRNA expression has been reported in lung inflammatory diseases such as asthma, chronic obstructive pulmonary disorder (COPD), cystic fibrosis (CF), idiopathic pulmonary fibrosis (IPF), pulmonary artery hypertension (PAH), and cardiovascular diseases such as atherosclerosis, myocardial infarction (MI), cardiac fibrosis, and coronary artery disease [8, 213]. Banerjee and Luettich reviewed the miRNAs as potential biomarkers for the major smoking-related diseases including cancer, COPD, PAH, and cardiovascular diseases [213]. Also, based on observations from human and mouse model they suggested miRNAs as regulators of biological responses, such as inflammation innate immune response, including TLR signaling. Identification of particular miRNAs within cells, tissues, or cellular free body fluids, with altered expression correlated with disease and/or its clinical development, could thus be exploited as potential biomarker for diagnosis and management. The potential of miRNAs to serve as biomarkers is further supported by their innate characteristics, such as high conservation between species, presence of highly stable cell-free form in the circulation, and omnipresence—being isolated from most of the cells, tissues, and body fluids including serum, plasma, urine, saliva, breast milk, tears, semen, exhaled breath condensate, and bronchoalveolar lavage fluid (BALF); importantly they can be detected in small sample volumes using quantitative real-time PCR (qRT-PCR) [5]. The observed stability, that is, resistance to enzymatic RNase A digestion and other conditions such as boiling, extreme pH, extended storage, and several cycles of freeze-thaw in serum [214] as well in plasma, is also relevant in this context [215].

4.1. Circulating miRNAs. Circulating miRNAs, also known as extracellular miRNAs in nature. The origin of circulating miRNAs, stable existence in extracellular environment, and their distinct roles, has remained elusive [193, 216]. They could be divided into two major groups, microparticles associated and microparticles nonassociated miRNAs [217, 218]. Circulating miRNAs are exported from cells and are transported with microparticles such as membrane-derivives (exosomes and microvesicles), lipoproteins (HDL), and other ribonucleoprotein complexes such as Nucleophosmin-1 (NPM-1) and Ago2-miRNA (Figure 1) that protect them against enzymatic degradation [193, 219]. Arroyo et al. characterized circulating miRNA complexes in human plasma and serum. For miRNA profiling, they quantified 88 plasma and 66 serum miRNAs by RT-qPCR and revealed that the vesicle-associated plasma miRNAs represent the minor fraction, whereas up to 90% of circulating miRNAs were present in a nonmembrane-bound form with ribonucloprotein complex [217].

Importantly, there are differences in miRNAs expression and abundance between the source, that is, serum and plasma and/or body fluids/other components [220–222]. For example, in the same individuals, higher miRNA concentrations were obtained from serum samples compared to the corresponding plasma samples. This difference was suggested due to release of additional miRNAs from blood cells into serum during the coagulation process. Plasma was suggested as sample of choice, representing true repertoire for circulatory miRNAs [221]. Still, concentration of circulating miRNAs in plasma may be affected by multiple factors such as sample processing, release by specific cells into the circulation, and also miRNA stability [223]. Recently, miRNAs from exosomes [77] and platelets [224] have also been explored and have distinct expression profile [218]. For research, one should consider in which components (body fluid types and microparticles) circulating miRNAs are investigated.

The differential expression of tissue-specific miRNAs in circulation has been explored as potential circulating biomarkers for specific organ pathologies involved in lung or heart disease, for example, skeletal muscle specific miR-1, -499, -133, and -206 in plasma of COPD patients [94] and cardiac specific miR-133a, -208a, and -499 in MI [154, 159, 160, 223]. Most of the miRNAs are significantly detectable in the diseased serum or plasma samples and this thus supports the possibility of using the expression levels of these organ-specific circulatory miRNAs as biomarkers for site-specific pathologies [221].

However, there are limitations and factors to be addressed prior to application of miRNAs in diagnostic purpose. These include optimal standardization in the approaches for obtaining sample (invasive/noninvasive), source (local/systemic), and nature (extra-cellular/cellular/tissue-based) of biological material and minimal variability in sample collection and its processing. Moreover, lack of data on miRNA specificity/sensitivity among different reports and its overlapping role in different diseases also hampers its applicability.

4.2. Current Developments in miRNA Based Approaches. The preliminary step includes quality estimation of miRNA. Among the few possibilities, 2100 Bioanalyzer, a lab on-chip technology from Agilent Technologies, offers both qualitative and quantitative estimation of miRNAs. For miRNA discovery, high-throughput deep sequencing (next-generation sequencing) platforms such as HiSeq 2000/Genome Analyzer IIX/Solexa (Illumina), SOLiD ( ABI), GS FLX+, or
454 sequencing (Roche) are available [225]. Amongst these, HiSeq 2000 solid phase technology supports massively parallel sequencing using a reversible terminator based method with least error rate and is most successful and widely adopted [226]. In the process of identification of miRNAs, several computational approaches have been developed that complement the experimental analysis. These in silico resources include MiRscam, miRSeeker, Phylogenetic shadowing, mirRank, mirDeep, MiRanalyzer, proMiR II, mirabela, triplet-SVM, Vmir, RNA micro, BayesMiRNAFind, One-ClassMirnaFind, miPred, Srnaloop, and findMiRNA [226]. Additionally, miRandola, an extracellular circulating miRNA database, allows users to deduce their potential biological functions and their relation with phenotypes [227].

Most commonly used techniques for establishing miRNA signatures in body fluids include high throughput determination of differential miRNA gene expression using miRNA microarrays [228] and their further validation using quantitative real-time PCR (qRT-PCR). However, the best approach for absolute quantification is qRT-PCR and its two variations, that is, stem-loop (TaqMan probe based) RT-PCR [229] and poly(A)-tailed (SYBR green based) RT-PCR [230], with improved specificity and sensitivity for miRNA expression analysis. Nonetheless, most published studies present conflicting data and have limitations in their cross-comparison of miRNA-expression profiles due to technical variations that include various reference genes being used to normalize the miRNA levels measured in body fluids and differences in blood collection (e.g., heparin contains an inhibitor of Taq polymerase) [231].

The optimal quantification of the target miRNAs involves data normalization using either stable reference genes under the study or accumulative values of the large scale miRNA-profiling data under study. However, as reference miRNAs (RNU6B, 5S rRNA) are reported to vary with the sample source and study type, former approach is suggested as preferred due to usage of global measure [232]. The addition of synthetic miRNAs from an unrelated organism such as C. elegans (cel-miR-39, cel-miR-54, and cel-miR-238) during miRNA isolation has also been proven useful for normalizing the data obtained by qRT-PCR [215]. Cheng et al. report plasma/serum volume as the best factor with which to standardize the amount of input miRNA [152]. However, studies are necessary for the identification of an accurate normalization protocol and empirical validation of stable endogenous control miRNAs for each type of body fluid.

For studying epigenetic modification, preliminary analysis involves methylated-DNA immunoprecipitation-chip (MeDIP-chip), validated differential methylation loci by bisulfate (BS) PCR and high throughput sequencing (BS-seq). The miRNA promoters in different cell types have been identified by genome-wide profiling of promoter associated chromatin marks through Dnase I hypersensitivity (DHS) mapping, chromatin immunoprecipitation (ChIP) followed by large-scale microarray analysis (DHS/ChIP-chip) or next-generation sequencing (DHS/ChIP-seq). DHS mapping identifies sites of open chromatin that are accessible to factors that influence gene expression. Active promoters are characterized by open chromatin regions enriched for both the H3K4me3 and H3K79me2 [42].

The use of miRNA as a target for therapeutic tool has remained as challenge due to its redundancy that involves nontarget-specific. Antisense oligonucleotides primarily work as competitive inhibitors of miRNAs by binding to the mature miRNA strand and inducing degradation or stable duplex formation and making it unavailable for RISC formation. The microRNA-based therapeutic approaches have been recently summarized in several reviews [8, 197, 233]. To minimize the miRNA dysregulation, the low expressed miRNAs could be restored through molecular strategies such as mimic miRNA or adenovirus associated vectors (AAV) carrying miRNA encoding gene. Conversely, the upregulated miRNAs could be optimally managed through usage of antagonirs, locked nucleic acid (LNA) anti-miR, miRNA sponge, and miR-masks. However, the major problems complicating the use of in vivo miRNA therapeutics appear in the phase of tissue-specific delivery or the cellular uptake of sufficient amounts of synthetic oligo to achieve sustained target inhibition [233]. Application of antagonirs/anti-miRs in the animal model has shown few significant promising results [84, 130, 184, 188]. For example, Thum et al. demonstrated inhibition of interstitial fibrosis and attenuation of cardiac dysfunction by in vivo silencing of miR-21 through specific antagonist in a mouse pressure-overload-induced disease model with reduced cardiac ERK-MAP (extracellular signal-regulated kinase-mitogen-activated protein) kinase activity [184]. In another study, therapeutic inhibition of miR-208a by systemic subcutaneous delivery of LNA-modified oligonucleotide (anti-miR-208a) during hypertension-induced heart failure in rat model demonstrated the potent and sustained silencing of miR-208 in the heart with improved cardiac function and survival [188]. Besides, later on it was demonstrated that treatment with anti-miR-208a can result in significant increase of another miRNA, miR-19b (8.8-fold, P < 0.05) in the diseased group [185]. Therefore, more studies are warranted to analyze the impact of anti-miR treatment on the complex miRNA interaction network. Besides the therapeutic demonstration for such molecular approaches in animal models, challenges still remain for its application in humans. Towards this approach, human trials have been ongoing using locked nucleic acid approach and AAV owing to their efficiency and minimal toxicity related to off-target effects [233].

5. Conclusion

miRNAs play crucial role in immune system development, maintenance, and function. miRNA dysregulation is implicated in inflammatory pulmonary diseases and cardiac remodeling. Studies of miRNAs role in disease pathomechanisms have been undergoing translation to diagnostic area. In this context, two approaches to exploitation of miRNAs as biomarkers have been emerging: (1) characterization of the miRNA pattern typical for a given disease/condition (i.e., expression profiling) and (2) determination of miRNAs present in body fluids (circulating miRNA), which relative
stability may add advantage to their potential use as biomarkers.

Regarding potential therapeutic applications of miRNAs, several approaches may be used to control pathological miRNA dysregulation. These range from the inhibition of pathologically upregulated miRNAs by anti-miRNA oligonucleotides/anatagomirs or miRNA mimics to potential delivery of a miRNA to maintain its physiological level in case of its downregulation in a disease. However, development of targeted therapies has remained challenging due to their possibilities of nonspecific targets or alteration in the general miRNAs and miRNA-miRNA interacting network. Additionally, the epigenetic modifications along with environmental factors as well as mutation within the seed region of miRNA are among the major issues affecting the miRNA based transcriptional control. Therefore, it would be imperative to evaluate the complex regulatory circuit between miRNA, mirSNPs, and epigenetic modifications that regulate the expression of numerous genes in the genome. Additional strategies, such as understanding of genes and the mechanism regulating the miRNAs, are still needed for early detection of disease progression for improving patient outcomes in lung and heart diseases. Taken together, measurement of altered miRNA expression serves as useful noninvasive approach for the diagnosis and prognosis of respiratory and cardiovascular disease. Further, the unique role of miRNAs should be explored for better clinical practices towards disease management.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

This work was supported by IGA_PULF_2013_009, 2014_012; CZ.1.05/2.1.00/01.0030; and CZ.1.07/2.3.00/30.0041. The authors thank Dr. Giovanna Castoldi for helpful advice.

References

[1] S. Buckingham, “The major world of microRNAs,” in Proceedings of the 2nd Horizon Symposium: Understanding the RNAissance, Nature Publishing Group, Scarborough, Me, USA, 2003.

[2] R. C. Lee, R. L. Feinbaum, and V. Ambros, “The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14,” Cell, vol. 75, no. 5, pp. 843–854, 1993.

[3] A. E. Pasquinielli, B. J. Reinhart, F. Slack et al., “Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA,” Nature, vol. 408, no. 6808, pp. 86–89, 2000.

[4] B. J. Reinhart, F. J. Slack, M. Basson et al., “The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans,” Nature, vol. 403, no. 6772, pp. 901–906, 2000.

[5] T. Blondal, S. J. Nielsen, A. Baker et al., “Assessing sample and miRNA profile quality in serum and plasma or other biofluids,” Methods, vol. 59, no. 1, pp. 81–86, 2013.

[6] E. P. Murchison and G. J. Hannon, “miRNAs on the move: miRNA biogenesis and the RNAi machinery,” Current Opinion in Cell Biology, vol. 16, no. 3, pp. 223–229, 2004.

[7] H. Y. Lee, K. Zhou, A. M. Smith, C. L. Noland, and J. A. Doudna, “Differential roles of human Dicer-binding proteins TRBP and PACT in small RNA processing,” Nucleic Acids Research, vol. 41, no. 13, pp. 6568–6576, 2013.

[8] R. Sessa and A. Hata, “Role of microRNAs in lung development and pulmonary diseases,” Pulmonary Circulation, vol. 3, no. 2, pp. 315–328, 2013.

[9] R. M. O’Connell, D. S. Rao, A. A. Chaudhuri, and D. Baltimore, “Physiological and pathological roles for microRNAs in the immune system,” Nature Reviews Immunology, vol. 10, no. 2, pp. 111–122, 2010.

[10] J. Yue, “miRNA and vascular cell movement,” Advanced Drug Delivery Reviews, vol. 63, no. 8, pp. 616–622, 2011.

[11] Z. Tan, G. Randall, J. Fan et al., “Allele-specific targeting of microRNAs to HLA-G and risk of asthma,” American Journal of Human Genetics, vol. 81, no. 4, pp. 829–834, 2007.

[12] X.-W. Su, Y. Yang, M.-L. Ly et al., “Association between single-nucleotide polymorphisms in pre-miRNAs and the risk of asthma in a Chinese population,” DNA and Cell Biology, vol. 30, no. 11, pp. 919–923, 2011.

[13] S. Jimenez-Morales, R. Gamboa-Becerra, V. Baca et al., “miR-146a polymorphism is associated with asthma but not with systemic lupus erythematosus and juvenile rheumatoid arthritis in Mexican patients,” Tissue Antigens, vol. 80, no. 4, pp. 317–321, 2012.

[14] R. W. Lung, X. Wang, J. Hung-Man et al., “A single nucleotide polymorphism in microRNA-146a is associated with the risk for nasopharyngeal carcinoma,” Molecular Carcinogenesis, vol. 52, supplement 1, pp. 28–38, 2013.

[15] J. Nicodemus-Johnson, B. Laxman, R. K. Stern et al., “Maternal asthma and microRNA regulation of soluble HLA-G in the airway,” The Journal of Allergy and Clinical Immunology, vol. 131, no. 6, pp. 1496–1503, 2013.

[16] Z. Hu, J. Chen, T. Tian et al., “Genetic variants of miRNA sequences and non-small cell lung cancer survival,” The Journal of Clinical Investigation, vol. 118, no. 7, pp. 2600–2608, 2008.

[17] K. A. Yoon, H. Yoon, S. Park et al., “The prognostic impact of microRNA sequence polymorphisms on the recurrence of patients with completely resected non-small cell lung cancer,” The Journal of Thoracic and Cardiovascular Surgery, vol. 144, no. 4, pp. 794–807, 2012.

[18] T. Tian, Y. Shu, J. Chen et al., “A functional genetic variant in microRNA-196a2 is associated with increased susceptibility of lung cancer in Chinese,” Cancer Epidemiology Biomarkers & Prevention, vol. 18, no. 4, pp. 1183–1187, 2009.

[19] S. Vinci, S. Gelmini, N. Pratesi et al., “Genetic variants in miR-146a, miR-149, miR-196a2, miR-499 and their influence on relative expression in lung cancers,” Clinical Chemistry and Laboratory Medicine, vol. 49, no. 12, pp. 2073–2080, 2011.

[20] J. Wang, Q. Wang, H. Liu et al., “The association of miR-146a rs2910164 and miR-196a2 rs1614913 polymorphisms with cancer risk: a meta-analysis of 32 studies,” Mutagenesis, vol. 27, no. 6, pp. 779–788, 2012.

[21] Z. Yuan, X. Zeng, D. Yang, W. Wang, and Z. Liu, “Effects of common polymorphism rs1614913 in Hsa-miR-196a2 on lung cancer risk,” PLoS ONE, vol. 8, no. 4, article e60147, 2013.

[22] L.-X. Qiu, Y. Wang, Z.-G. Xia et al., “miR-196a2 C allele is a low-penetrant risk factor for cancer development,” Cytokine, vol. 56, no. 3, pp. 589–592, 2011.
[23] F. Wang, Y.-L. Ma, P. Zhang et al., "A genetic variant in microRNA-196a2 is associated with increased cancer risk: a meta-analysis," *Molecular Biology Reports*, vol. 39, no. 1, pp. 269–275, 2012.
[24] J. Xu, Z. Hu, Z. Xu et al., "Functional variant in microRNA-196a2 contributes to the susceptibility of congenital heart disease in a Chinese population," *Human Mutation*, vol. 30, no. 8, pp. 1231–1236, 2009.
[25] L.-J. Li, L.-B. Gao, M.-L. Lv et al., "Association between SNPs in pre-miRNA and risk of chronic obstructive pulmonary disease," *Clinical Biochemistry*, vol. 44, no. 10–11, pp. 813–816, 2011.
[26] D. Li, T. Wang, X. Song et al., "Genetic study of two single nucleotide polymorphisms within corresponding microRNAs and susceptibility to tuberculosis in a Chinese Tibetan and Han population," *Human Immunology*, vol. 72, no. 7, pp. 598–602, 2011.
[27] K. D. Taganov, M. P. Boldin, K.-J. Chang, and D. Baltimore, "NF-kB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 103, no. 33, pp. 12481–12486, 2006.
[28] H. Kikami, A. Kawasaki, I. Ito et al., "Association of a functional polymorphism in the 3′-untranslated region of SPI1 with systemic lupus erythematosus," *Arthritis & Rheumatism*, vol. 63, no. 3, pp. 755–763, 2011.
[29] X. Luo, W. Yang, D.-Q. Ye et al., "A functional variant in microRNA-146a promoter modulates its expression and confers disease risk for systemic lupus erythematosus," *PLoS Genetics*, vol. 7, no. 6, article e1002128, 2011.
[30] R. X. Leng, W. Wang, H. Cen et al., "Gene–gene and gene–sex epistatic interactions of MiR146a, IRF5, IKZF1, ETSl and IL21 in systemic lupus erythematosus," *PLoS ONE*, vol. 7, no. 12, article e51090, 2012.
[31] S. E. Lofgren, J. Frostegård, L. Truedsson et al., "Genetic association of miRNA-146a with systemic lupus erythematosus in Europeans through decreased expression of the gene," *Genes & Immunity*, vol. 13, no. 3, pp. 268–274, 2012.
[32] Y. Deng, J. Zhao, D. Sakurai et al., "MicroRNA-3148 modulates allelic expression of toll-like receptor 7 variant associated with systemic lupus erythematosus," *PLoS Genetics*, vol. 9, no. 2, article e1003336, 2013.
[33] F. Amato, M. Seia, S. Giordano et al., "Gene mutation in microRNA target sites of CFTR gene: a novel pathogenetic mechanism in cystic fibrosis?" *PLoS ONE*, vol. 8, no. 3, article e60448, 2013.
[34] Y. Tang, X. Luo, H. Cui et al., "MicroRNA-146a contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins," *Arthritis & Rheumatism*, vol. 60, no. 4, pp. 1065–1075, 2009.
[35] T. S. Elton, S. E. Sansom, and M. M. Martin, "Cardiovascular disease, single nucleotide polymorphisms, and the renin angiotensin system: is there a microRNA connection?" *International Journal of Hypertension*, vol. 2010, Article ID 281692, 13 pages, 2010.
[36] P. Sethupathy, C. Borel, M. Gagnebin et al., "Human microRNA-155 on chromosome 21 differentially interacts with its polymorphic target in the AGTR1 3′ untranslated region: a mechanism for functional single-nucleotide polymorphisms related to phenotypes," *American Journal of Human Genetics*, vol. 81, no. 2, pp. 405–413, 2007.
[37] U. Haas, G. Szczakiel, and S. D. Lauffer, "MicroRNA-mediated regulation of gene expression is affected by disease-associated SNPs within the 3′-UTR via altered RNA structure," *RNA Biology*, vol. 9, no. 6, pp. 924–937, 2012.
[38] B. Mopidevi, M. Ponnala, and A. Kumar, "Human angiotensinogen-11525 C/A polymorphism modulates its gene expression through microRNA binding," *Physiological Genomics*, vol. 45, no. 19, pp. 901–906, 2013.
[39] C. Wu, Y. Gong, A. Sun et al., "The human MTHFR rs4846049 polymorphism increases coronary heart disease risk through modifying miRNA binding," *Nutrition, Metabolism & Cardiovascular Diseases*, vol. 23, no. 7, pp. 693–698, 2013.
[40] S.-L. Ding, J.-X. Wang, J.-Q. Jiao et al., "A pre-microRNA-149 (miR-149) genetic variation affects miR-149 maturation and its ability to regulate the Puma protein in apoptosis," *The Journal of Biological Chemistry*, vol. 288, no. 37, pp. 26865–26877, 2013.
[41] B. Zhou, L. Rao, Y. Peng et al., "Common genetic polymorphisms in pre-microRNAs were associated with increased risk of dilated cardiomyopathy," *Clinica Chimica Acta*, vol. 411, no. 17–18, pp. 1287–1290, 2010.
[42] P. Sethupathy, "Illuminating microRNA transcription from the epigenome," *Current Genomics*, vol. 14, no. 1, pp. 68–77, 2013.
[43] T. A. Volpe, C. Kidner, I. M. Hall, G. Teng, S. I. S. Grewal, and R. A. Martienssen, "Regulation of heterochromatic silencing and histone H3 lysine-9 methylation by RNAi," *Science*, vol. 297, no. 5588, pp. 1833–1837, 2002.
[44] C. Baer, R. Claus, and C. Plass, "Genome-wide epigenetic regulation of miRNAs in cancer," *Cancer Research*, vol. 73, no. 2, pp. 473–477, 2013.
[45] C.-W. Lin, Y.-L. Chang, Y.-C. Chang et al., "MicroRNA-135b promotes lung cancer metastasis by regulating multiple targets in the Hippo pathway and LZTS1," *Nature Communications*, vol. 4, Article ID 1877, 2013.
[46] M. Fabbris, R. Garzon, A. Cimmino et al., "MicroRNA-29 family reverses aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 104, no. 40, pp. 15805–15810, 2007.
[47] A. Lujambio and S. W. Lowe, "The microcosmos of cancer," *Nature*, vol. 482, no. 7385, pp. 347–355, 2012.
[48] B. Brueckner, C. Stresemann, R. Kuner et al., "The human let-7a-3 locus contains an epigenetically regulated microRNA gene with oncogenic function," *Cancer Research*, vol. 67, no. 4, pp. 1419–1423, 2007.
[49] T. Kunej, I. Godnic, J. Ferdin, S. Horvat, P. Dovec, and G. A. Calin, "Epigenetic regulation of microRNAs in cancer: an integrated review of literature," *Mutation Research*, vol. 717, no. 1–2, pp. 77–84, 2011.
[50] N. Tanaka, S. Toyooka, J. Soh et al., "Frequent methylation and oncogenic role of microRNA-34b/c in small-cell lung cancer," *Lung Cancer*, vol. 76, no. 1, pp. 32–38, 2012.
[51] D. Lodygin, V. Tarasov, A. Epanchintsev et al., "Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer," *Cell Cycle*, vol. 7, no. 16, pp. 2591–2600, 2008.
[52] B. Richardson, "Effect of an inhibitor of DNA methylation on T cells. II. 5-Azacytidine induces self-reactivity in antigen-specific T4 cells," *Human Immunology*, vol. 17, no. 4, pp. 456–470, 1986.
[53] B. Richardson, L. Scheinhart, J. Strahler, L. Gross, S. Hanash, and M. Johnson, "Evidence for impaired T cell DNA methylation in systemic lupus erythematosus and rheumatoid arthritis," *Arthritis & Rheumatism*, vol. 33, no. 11, pp. 1665–1673, 1990.
[54] C. Deng, Q. Lu, Z. Zhang et al., "Hydralazine may induce autoimmunity by inhibiting extracellular signal-regulated..."
Mediators of Inflammation

[87] A. Collison, J. Mattes, M. Plank, and P. S. Foster, “Inhibition of house dust mite-induced allergic airways disease by antagonism of microRNA-145 is comparable to glucocorticoid treatment,” The Journal of Allergy and Clinical Immunology, vol. 128, no. 1, pp. 160.e4–167.e4, 2011.

[88] M. J. Feng, F. Shi, C. qiu, and W.-K. Peng, “MicroRNA-181a, -146a and -146b in spleen CD4+ T lymphocytes play proinflammatory roles in a murine model of asthma,” International Immunopharmacology, vol. 13, no. 3, pp. 347–353, 2012.

[89] Y. Zheng, S. Xiong, P. Jiang et al., “Glucocorticoids inhibit lipopolysaccharide-mediated inflammatory response by down-regulating microRNA-155: a novel anti-inflammation mechanism,” Free Radical Biology and Medicine, vol. 52, no. 8, pp. 1307–1317, 2012.

[90] R. J. Mayoral, L. Deho, N. Rusca et al., “MiR-221 influences effector functions and actin cytoskeleton in mast cells,” PLoS ONE, vol. 6, no. 10, article e26133, 2011.

[91] M. M. Perry, J. E. Baker, D. S. Gideon, I. M. Adcock, and K. E. Chung, “Airway smooth muscle hyperproliferation is regulated by microRNA-221 in severe asthma,” American Journal of Respiratory and Cell Molecular Biology, vol. 50, no. 1, pp. 7–17, 2014.

[92] G. R. Pottelberge, P. Mestdagh, K. R. Bracke et al., “MicroRNA expression in induced sputum of smokers and patients with chronic obstructive pulmonary disease,” American Journal of Respiratory and Critical Care Medicine, vol. 183, no. 7, pp. 898–906, 2011.

[93] A. Lewis, J. Riddoch-Contreras, S. A. Natanek et al., “Down-regulation of the serum response factor/miR-1 axis in the quadricipits of patients with COPD,” Thorax, vol. 67, no. 1, pp. 26–34, 2012.

[94] A. Donaldson, S. A. Natanek, A. Lewis et al., “Increased skeletal muscle-specific microRNA in the blood of patients with COPD,” Thorax, vol. 68, no. 12, pp. 1140–1149, 2013.

[95] F. Akbas, E. Coskunpınar, E. Aynac, Y. M. Oltulu, and P. Yildiz, “Analysis of serum micro-RNAs as potential biomarker in chronic obstructive pulmonary disease,” Experimental Lung Research, vol. 38, no. 6, pp. 286–294, 2012.

[96] M. E. Ezzie, M. Crawford, J.-H. Cho et al., “Gene expression networks in COPD: microRNA and mRNA regulation,” Thorax, vol. 67, no. 2, pp. 122–131, 2012.

[97] F. Schembri, S. Sridhar, C. Perdomo et al., “MicroRNAs as modulators of smoking-induced gene expression changes in human airway epithelium,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 7, pp. 2319–2324, 2009.

[98] F. Hassan, G. I. Nuovo, M. Crawford et al., “MiR-101 and miR-144 regulate the expression of the CFTR chloride channel in the lung,” PLoS ONE, vol. 7, no. 11, article e50837, 2012.

[99] J. W. Graff, L. S. Powers, A. M. Dickson et al., “Cigarette smoking decreases global microRNA expression in human alveolar macrophages,” PLoS ONE, vol. 7, no. 8, article e44066, 2012.

[100] A. E. Gillen, N. Gosalia, S. -H. Leir, and A. Harris, “microRNA regulation of expression of the cystic fibrosis transmembrane conductance regulator gene,” The Biochemical Journal, vol. 438, no. 1, pp. 25–32, 2011.

[101] F. Megiorni, S. Cialfi, C. Dominici, S. Quattrucci, and A. Pizzuti, “Synergistic post-transcriptional regulation of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) by miR-101 and miR-494 specific binding,” PLoS ONE, vol. 6, no. 10, article e26601, 2011.

[102] I. K. Oglesby, I. M. Bray, S. H. Chotirmall et al., “miR-126 is downregulated in cystic fibrosis airway epithelial cells and regulates TOMI expression,” The Journal of Immunology, vol. 184, no. 4, pp. 1702–1709, 2010.

[103] S. Ramachandran, P. H. Karp, P. Jiang et al., “A microRNA network regulates expression and biosynthesis of wild-type and ΔF508 mutant cystic fibrosis transmembrane conductance regulator,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 33, pp. 13362–13367, 2012.

[104] I. K. Oglesby, S. H. Chotirmall, N. G. McElvaney, and C. M. Greene, “Regulation of cystic fibrosis transmembrane conductance regulator by microRNA-145, -223, and -494 is altered in ΔF508 cystic fibrosis airway epithelium,” The Journal of Immunology, vol. 190, no. 7, pp. 3354–3362, 2013.

[105] F. Megiorni, S. Cialfi, G. Cimino et al., “Elevated levels of miR-145 correlate with SMAD3 down-regulation in Cystic Fibrosis patients,” Journal of Cystic Fibrosis, vol. 12, no. 6, pp. 797–802, 2013.

[106] N. Pottier, T. Maurin, B. Chevalier et al., “Identification of keratinocyte growth factor as a target of microRNA-155 in lung fibroblasts: implication in epithelial-mesenchymal interactions,” PLoS ONE, vol. 4, no. 8, article e6718, 2009.

[107] S. Bhattacharyya, N. S. Balakathiresan, C. Dalgard et al., “Elevated miR-155 promotes inflammation in cystic fibrosis by driving hyperexpression of interleukin-8,” The Journal of Biological Chemistry, vol. 286, no. 13, pp. 11604–11615, 2011.

[108] M. Tsuchiya, P. Kumar, S. Bhattacharyya et al., “Differential regulation of inflammation by inflammatory mediators in cystic fibrosis lung epithelial cells,” Journal of Interferon & Cytokine Research, vol. 33, no. 3, pp. 121–129, 2013.

[109] S. Bhattacharyya, P. Kumar, M. Tsuchiya, A. Bhattacharyya, and R. Biswas, “Regulation of miR-155 biogenesis in cystic fibrosis lung epithelial cells: antagonistic role of two mRNA destabilizing proteins, KSRP and ‘TTP’,” Biochemical and Biophysical Research Communications, vol. 433, no. 4, pp. 484–488, 2013.

[110] S. Ramachandran, P. H. Karp, S. R. Osterhaus et al., “Post-transcriptional regulation of cystic fibrosis transmembrane conductance regulator expression and function by microRNAs,” American Journal of Respiratory Cell and Molecular Biology, vol. 49, no. 4, pp. 544–551, 2013.

[111] K. V. Pandit, D. Corcoran, H. Yousef et al., “Inhibition and role of let-7d in idiopathic pulmonary fibrosis,” American Journal of Respiratory and Critical Care Medicine, vol. 182, no. 2, pp. 220–229, 2010.

[112] S. R. Oak, L. Murray, A. Herath et al., “A microRNA processing defect in rapidly progressing idiopathic pulmonary fibrosis,” PLoS ONE, vol. 6, no. 6, article e21253, 2011.

[113] D. Dakhllallah, “Cross-talk between epigenetic regulation and Mir-17–92 cluster expression in idiopathic pulmonary fibrosis (IPF) [Ph.D. dissertation], The Ohio State University, Columbus, Ohio, USA, 2011.

[114] M. Yamada, H. Kubo, C. Ota et al., “The increase of microRNA-21 during lung fibrosis and its contribution to epithelial-mesenchymal transition in pulmonary epithelial cells,” Respiratory Research, vol. 14, no. 1, article 95, 2013.

[115] L. Cushing, P. P. Kuang, J. Qian et al., “miR-29 is a major regulator of genes associated with pulmonary fibrosis,” American Journal of Respiratory Cell and Molecular Biology, vol. 45, no. 2, pp. 287–294, 2011.
[116] K. V. Pandit, J. Milosevic, and N. Kaminski, “MicroRNAs in idiopathic pulmonary fibrosis,” *Translational Research*, vol. 157, no. 4, pp. 191–199, 2011.

[117] J. Xiao, X.-M. Meng, X. R. Huang et al., “miR-29 inhibits bleomycin-induced pulmonary fibrosis in mice,” *Molecular Therapy*, vol. 20, no. 6, pp. 1251–1260, 2012.

[118] J. Milosevic, K. Pandit, M. Magister et al., “Profibrotic role of miR-154 in pulmonary fibrosis,” *American Journal of Respiratory Cell and Molecular Biology*, vol. 47, no. 6, pp. 879–887, 2012.

[119] T. Xie, J. Liang, N. Liu et al., “MicroRNA-127 inhibits lung inflammation by targeting IgG Fcy receptor I,” *The Journal of Immunology*, vol. 188, no. 5, pp. 2437–2444, 2012.

[120] K. Vapori, E. Vergadi, E. Kaniaris et al., “Pulmonary microRNA profiling in a mouse model of ventilator-induced lung injury,” *American Journal of Physiology: Lung Cellular and Molecular Physiology*, vol. 303, no. 3, pp. L199–L207, 2012.

[121] N. Yehya, A. Yerrapureddy, J. Tobias, and S. S. Margulies, “MicroRNA modulate alveolar epithelial response to cyclic stretch,” *RMC Genomics*, vol. 13, article 154, 2012.

[122] Z. Zeng, H. Gong, Y. Li et al., “Upregulation of miR-146a contributes to the suppression of inflammatory responses in LPS-induced acute lung injury,” *Experimental Lung Research*, vol. 39, no. 7, pp. 275–282, 2013.

[123] M. M. Perry, S. A. Moschos, A. E. Williams, N. J. Shepherd, H. M. Larner-Svensson, and M. A. Lindsay, “Rapid changes in microRNA-146a expression negatively regulate the IL-1β-induced inflammatory response in human lung alveolar epithelial cells,” *The Journal of Immunology*, vol. 180, no. 8, pp. 5689–5698, 2008.

[124] X. Sun, B. Icli, A. K. Wara et al., “MicroRNA-181b regulates NF-κB-mediated vascular inflammation,” *The Journal of Clinical Investigation*, vol. 122, no. 6, pp. 1973–1990, 2012.

[125] M. Brock, M. Trenkmann, R. E. Gay et al., “Interleukin-6 modulates the expression of the bone morphogenic protein receptor type II through a novel STAT3-microRNA cluster 17/92 pathway,” *Circulation Research*, vol. 104, no. 10, pp. 1184–1191, 2009.

[126] J. Sarkar, D. Gou, P. Turaka, E. Vitorova, R. Ramchandran, and J. U. Raj, “MicroRNA-21 plays a role in hypoxia-mediated pulmonary artery smooth muscle cell proliferation and migration,” *American Journal of Physiology: Lung Cellular and Molecular Physiology*, vol. 299, no. 6, pp. L861–L871, 2010.

[127] S. Yang, S. Banerjee, A. de Freitas et al., “miR-21 regulates chronic hypoxia-induced pulmonary vascular remodeling,” *American Journal of Physiology: Lung Cellular and Molecular Physiology*, vol. 302, no. 6, pp. L521–L529, 2012.

[128] C. Y. Wei, H. Henderson, C. Spradley et al., “Circulating miRNAs as potential marker for pulmonary hypertension,” *PLoS ONE*, vol. 8, no. 5, article e64396, 2013.

[129] K. Kang, X. Peng, X. Zhang et al., “MicroRNA-124 suppresses the transactivation of nuclear factor of activated T cells by targeting multiple genes and inhibits the proliferation of pulmonary artery smooth muscle cells,” *The Journal of Biological Chemistry*, vol. 288, no. 35, pp. 25414–25427, 2013.

[130] P. Caruso, Y. Dempsey, H. C. Stevens et al., “A role for miR-145 in pulmonary arterial hypertension: evidence from mouse models and patient samples,” *Circulation Research*, vol. 111, no. 3, pp. 290–300, 2012.

[131] A. Courboulin, R. Paulin, N. J. Giguère et al., “Role for miR-204 in human pulmonary arterial hypertension,” *Journal of Experimental Medicine*, vol. 208, no. 3, pp. 535–548, 2011.

[132] S. Jalali, G. K. Ramanathan, P. T. Parthasarathy et al., “Mir-206 regulates pulmonary artery smooth muscle cell proliferation and differentiation,” *PLoS ONE*, vol. 7, no. 10, article e46808, 2012.

[133] J. Yue, J. Guan, X. Wang et al., “MicroRNA-206 is involved in hypoxia-induced pulmonary hypertension through targeting of the HIF-1α/FLT-1 pathway,” *Laboratory Investigation*, vol. 93, no. 7, pp. 748–759, 2013.

[134] J. Kim, Y. Kang, Y. Koijima et al., “An endothelial apelin-FGF link mediated by miR-424 and miR-503 is disrupted in pulmonary arterial hypertension,” *Nature Medicine*, vol. 19, no. 1, pp. 74–82, 2013.

[135] G. Raghu, H. R. Collard, J. J. Egan et al., “An official ATS/ERS/JS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management,” *American Journal of Respiratory and Critical Care Medicine*, vol. 183, no. 6, pp. 788–824, 2011.

[136] T. Yang, G.-F. Zhang, X.-F. Chen et al., “MicroRNA-214provokes cardiac hypertrophy via repression of EZH2,” *Biochemical and Biophysical Research Communications*, vol. 436, no. 4, pp. 578–584, 2013.

[137] E. Orenes-Pinero, S. Montoro-García, J. V. Patel, M. Valdés, F. Marin, and G. Y. Lip, “Role of microRNAs in cardiac remodelling: new insights and future perspectives,” *International Journal of Cardiology*, vol. 167, no. 5, pp. 1651–1659, 2013.

[138] G. Condorelli, M. V. Latronico, and E. Cavarretta, “microRNAs in cardiovascular diseases: current knowledge and the road ahead,” *Journal of the American College of Cardiology*, 2014.

[139] P. Libby, “Inflammation and cardiovascular disease mechanisms,” *The American Journal of Clinical Nutrition*, vol. 83, no. 2, pp. 456S–460S, 2006.

[140] L. Xiao, Y. Liu, and N. Wang, “New paradigms in inflammatory signaling in vascular endothelial cells,” *American Journal of Physiology: Heart and Circulatory Physiology*, 2013.

[141] J. Baurersachs and T. Thum, “Biogenesis and regulation of cardiovascular microRNAs,” *Circulation Research*, vol. 109, no. 3, pp. 334–347, 2011.

[142] R. Ranjha and J. Paul, “Micro-RNAs in inflammatory diseases and as a link between inflammation and cancer,” *Inflammation Research*, vol. 62, no. 4, pp. 343–355, 2013.

[143] E. Raitoharju, L.-P. Lyytikäinen, M. Levula et al., “miR-21, miR-210, miR-34a, and miR-146a/b are up-regulated in human atherosclerotic plaques in the Tampere Vascular Study,” *Atherosclerosis*, vol. 219, no. 1, pp. 211–217, 2011.

[144] K. Bidzhekov, L. Gan, B. Denecke et al., “microRNA expression signatures and parallels between monocyte subsets and atherosclerotic plaque in humans,” *Thrombosis and Haemostasis*, vol. 107, no. 4, pp. 619–625, 2012.

[145] K.-C. Chen, Y.-C. Liao, I.-C. Hsieh, Y.-S. Wang, C.-Y. Hu, and S.-H. H. Juo, “OxLDL causes both epigenetic modification and as a link between inflammation and cancer,” *Inflammation Research*, vol. 62, no. 4, pp. 343–355, 2013.

[146] R. Ranjha and J. Paul, “Micro-RNAs in inflammatory diseases and as a link between inflammation and cancer,” *Inflammation Research*, vol. 62, no. 4, pp. 343–355, 2013.

[147] E. Raitoharju, L.-P. Lyytikäinen, M. Levula et al., “miR-21, miR-210, miR-34a, and miR-146a/b are up-regulated in human atherosclerotic plaques in the Tampere Vascular Study,” *Atherosclerosis*, vol. 219, no. 1, pp. 211–217, 2011.

[148] K. Bidzhekov, L. Gan, B. Denecke et al., “microRNA expression signatures and parallels between monocyte subsets and atherosclerotic plaque in humans,” *Thrombosis and Haemostasis*, vol. 107, no. 4, pp. 619–625, 2012.
Mediators of Inflammation

[148] G. Long, F. Wang, Q. Duan et al., “Circulating miR-30a, miR-195 and let-7b associated with acute myocardial infarction,” *PLoS ONE*, vol. 7, no. 12, article e50926, 2012.

[149] J. Ai, R. Zhang, Y. Li et al., “Circulating microRNA-1 as a potential novel biomarker for acute myocardial infarction,” *Biochemical and Biophysical Research Communications*, vol. 391, no. 1, pp. 73–77, 2010.

[150] S. Dimmeler and A. M. Zeiher, “Circulating microRNAs: novel biomarkers for cardiovascular diseases?” *European Heart Journal*, vol. 31, no. 22, pp. 2705–2707, 2010.

[151] Y. D’Alessandra, P. Devanna, F. Limana et al., “Circulating microRNAs as biomarkers and potential paracrine mediators of cardiovascular disease,” *Circulation: Cardiovascular Genetics*, vol. 3, no. 5, pp. 484–488, 2010.

[152] Y. Cheng, N. Tan, J. Yang et al., “A translational study of circulating cell-free microRNA-1 in acute myocardial infarction,” *Clinical Science*, vol. 119, no. 2, pp. 87–95, 2010.

[153] G. Long, F. Wang, Q. Duan et al., “Human circulating microRNA-1 and microRNA-126 as potential novel indicators for acute myocardial infarction,” *International Journal of Biological Sciences*, vol. 8, no. 6, pp. 811–818, 2012.

[154] G.-K. Wang, J.-Q. Zhu, J.-T. Zhang et al., “Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans,” *European Heart Journal*, vol. 31, no. 6, pp. 659–666, 2010.

[155] S. Dong, Y. Cheng, J. Yang et al., “MicroRNA expression signature and the role of microRNA-21 in the early phase of acute myocardial infarction,” *The Journal of Biological Chemistry*, vol. 284, no. 43, pp. 29514–29525, 2009.

[156] Y. D’Alessandra, P. Devanna, F. Limana et al., “Circulating microRNAs are new and sensitive biomarkers of myocardial infarction,” *European Heart Journal*, vol. 31, no. 22, pp. 2765–2773, 2010.

[157] R. Wang, N. Li, Y. Zhang, Y. Ran, and J. Pu, “Circulating microRNAs are promising novel biomarkers of acute myocardial infarction,” *Internal Medicine*, vol. 50, no. 17, pp. 1789–1795, 2011.

[158] A. J. Tijsen, Y. M. Pinto, and E. E. Creemers, “Non-cardiomyocyte microRNAs in heart failure,” *Cardiovascular Research*, vol. 93, no. 4, pp. 573–582, 2012.

[159] M. E. Corsten, R. Dennert, S. Jochems et al., “Circulating MicroRNA-208b and MicroRNA-499 reflect myocardial damage in cardiovascular disease,” *Circulation: Cardiovascular Genetics*, vol. 3, no. 6, pp. 499–506, 2010.

[160] T. Adachi, M. Nakanishi, Y. Otsuka et al., “Plasma microRNA 499 as a biomarker of acute myocardial infarction,” *Clinical Chemistry*, vol. 56, no. 7, pp. 1183–1185, 2010.

[161] L. Li, X.-W. Song, J. Zou et al., “Attenuation of microRNA-1 derepresses the cytoskeleton regulatory protein twinfilin-1 to provoke cardiac hypertrophy,” *Journal of Cell Science*, vol. 123, part 14, pp. 2444–2452, 2010.

[162] Y. Cheng, R. Ji, J. Yue et al., “MicroRNAs are aberrantly expressed in hypertrophic heart: do they play a role in cardiac hypertrophy?” *The American Journal of Pathology*, vol. 170, no. 6, pp. 1831–1840, 2007.

[163] Z. P. Huang, J. Chen, H. Y. Seok et al., “MicroRNA-22 regulates cardiac hypertrophy and remodeling in response to stress,” *Circulation Research*, vol. 112, no. 9, pp. 1234–1243, 2013.

[164] J. Wang, Y. Song, Y. Zhang et al., “Cardiomyocyte overexpression of miR-27b induces cardiac hypertrophy and dysfunction in mice,” *Cell Research*, vol. 22, no. 3, pp. 516–527, 2012.

[165] R. Roncarati, C. V. Anselmi, M. A. Losi et al., “Circulating miR-29a, among other up-regulated microRNAs, is the only biomarker for both hypertrophy and fibrosis in patients with hypertrophic cardiomyopathy,” *Journal of the American College of Cardiology*, vol. 63, no. 9, pp. 920–927, 2014.

[166] W. Pan, Y. Zhong, C. Cheng et al., “MiR-30-regulated autophagy mediates angiotensin II-induced myocardial hypertrophy,” *PLoS ONE*, vol. 8, no. 1, article e53950, 2013.

[167] A. Care, D. Catalucci, F. Felicetti et al., “MicroRNA-133 controls cardiac hypertrophy,” *Nature Medicine*, vol. 13, no. 5, pp. 613–618, 2007.

[168] D.-L. Dong, C. Chen, R. Huo et al., “Reciprocal repression between microRNA-133 and calcineurin regulates cardiac hypertrophy: a novel mechanism for progressive cardiac hypertrophy,” *Hypertension*, vol. 55, no. 4, pp. 946–952, 2010.

[169] S. Himans, M. E. Corsten, W. Verhesen et al., “Circulating microRNA-155 promotes cardiac hypertrophy and failure,” *Circulation*, vol. 128, no. 13, pp. 1420–1432, 2013.

[170] E. M. Small, R. J. A. Frost, and E. N. Olson, “MicroRNAs add a new dimension to cardiovascular disease,” *Circulation*, vol. 121, no. 8, pp. 1022–1032, 2010.

[171] D. Sayed, M. He, Z. Yang, and M. Abdellatif, “MicroRNA-21 enhances Akt activity and reduces myocyte apoptosis and ischemic heart failure through suppression of PTEN,” *Circulation*, vol. 120, no. 18, article e5838, 2009.

[172] Y. Tu, L. Wan, Y. Fan et al., “Ischemic postconditioning-mediated microRNA-21 protects against cardiac ischemia/reperfusion injury via PTEN/Akt pathway,” *PLoS ONE*, vol. 8, no. 10, article e75872, 2013.

[173] K. Kin, S. Miyagawa, S. Fukushima et al., “Tissue- and plasma-specific MicroRNA signatures for atherosclerotic abdominal aortic aneurysm,” *Journal of the American Heart Association*, vol. 1, no. 5, Article ID e000745, 2012.

[174] G. Castoldi, C. R. T. di Gioia, C. Bombardi et al., “MiR-133a regulates collagen 1A1: potential role of miR-133a in myocardial fibrosis in angiotensin II-dependent hypertension,” *Journal of Cellular Physiology*, vol. 227, no. 2, pp. 850–856, 2012.

[175] C. Wei, I. K. Kim, S. Kumar et al., “NF-κB mediated miR-26a regulation in cardiac fibrosis,” *Journal of Cellular Physiology*, vol. 228, no. 7, pp. 1433–1442, 2013.

[176] R. F. Duisters, A. J. Tijsen, B. Schroen et al., “miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microsnRNAs in myocardial matrix remodeling,” *Circulation Research*, vol. 104, no. 2, pp. 170–178, 2009.

[177] J. Beaumont, B. López, N. Hermida et al., “microRNA-122 down-regulation may play a role in severe myocardial fibrosis in human aortic stenosis through TGF-β1 up-regulation,” *Clinical Science*, vol. 126, no. 7, pp. 497–506, 2014.

[178] S. Fichtlscherer, S. de Rosa, H. Fox et al., “Circulating microRNAs in patients with coronary artery disease,” *Circulation Research*, vol. 107, no. 5, pp. 677–684, 2010.

[179] V. P. van Empel, L. J. de Windt, and P. A. da Costa Martins, “Circulating miRNAs: reflecting or affecting cardiovascular disease?” *Current Hypertension Reports*, vol. 14, no. 6, pp. 498–509, 2012.

[180] J. Ren, J. Zhang, N. Xu et al., “Signature of circulating microRNAs as potential biomarkers in vulnerable coronary artery disease,” *PLoS ONE*, vol. 8, no. 12, article e80738, 2013.

[181] M. Hoekstra, C. A. C. van der Lans, B. Halvorsen et al., “The peripheral blood mononuclear cell microRNA signature of coronary artery disease,” *Biochemical and Biophysical Research Communications*, vol. 394, no. 3, pp. 792–797, 2010.
[215] P. S. Mitchell, R. K. Parkin, E. M. Kroh et al., "Circulating microRNAs as stable blood-based markers for cancer detection," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 105, no. 30, pp. 10513–10518, 2008.

[216] A. Etheridge, I. Lee, L. Hood, D. Galas, and K. Wang, "Extracellular microRNA: a new source of biomarkers," *Mutation Research*, vol. 717, no. 1-2, pp. 85–90, 2011.

[217] J. D. Arroyo, J. R. Chevillet, E. M. Kroh et al., "Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 108, no. 12, pp. 5003–5008, 2011.

[218] P. Diehl, A. Fricke, L. Sander et al., "Microparticles: major transport vehicles for distinct microRNAs in circulation," *Cardiovascular Research*, vol. 93, no. 4, pp. 633–644, 2012.

[219] R. A. Boon and K. C. Vickers, "Intercellular transport of microRNAs," *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 33, no. 2, pp. 186–192, 2013.

[220] H. H. Cheng, H. S. Yi, Y. Kim et al., "Plasma processing conditions substantially influence circulating microRNA biomarker levels," *PLoS ONE*, vol. 8, no. 6, article e64795, 2013.

[221] K. Wang, Y. Yuan, J.-H. Cho, S. McClarty, D. Baxter, and D. J. Galas, "Comparing the MicroRNA spectrum between serum and plasma," *PLoS ONE*, vol. 7, no. 7, article e41561, 2012.

[222] J. A. Weber, D. H. Baxter, S. Zhang et al., "The microRNA spectrum in 12 body fluids," *Clinical Chemistry*, vol. 56, no. 11, pp. 1733–1741, 2010.

[223] S. de Rosa, S. Fichtlscherer, R. Lehmann, B. Assmus, S. Dimmeler, and A. M. Zeiher, "Transcoronary concentration gradients of circulating MicroRNAs," *Circulation*, vol. 124, no. 18, pp. 1936–1944, 2011.

[224] P. Willeit, A. Zampetaki, K. Dudek et al., "Circulating microRNAs as novel biomarkers for platelet activation," *Circulation Research*, vol. 112, no. 4, pp. 595–600, 2013.

[225] H. J. Peltier and G. J. Latham, "Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid tissues," *RNA*, vol. 14, no. 5, pp. 844–852, 2008.

[226] P. Mestdagh, P. van Vlierberghe, A. de Weer et al., "A novel and universal method for microRNA RT-qPCR data normalization," *Genome Biology*, vol. 10, no. 6, article R64, 2009.

[233] R. Garzon, G. Marcucci, and C. M. Croce, “Targeting microRNAs in cancer: rationale, strategies and challenges,” *Nature Reviews: Drug Discovery*, vol. 9, no. 10, pp. 775–789, 2010.